PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
26260011-6	2015	As expected for interactions involving multiple GSL binding sites at a viral capsid, the detachment kinetics displayed features typical for a broad activation-energy distribution for all GSLs.	Glycosphingolipids	187-191	cathepsin A	Homo sapiens	48-51
26503655-5	2016	Knockdown of CatA expression with RNA interference (RNAi) in HeLa cells reduced intracellular TAF metabolism 5-fold.	taf	94-97	cathepsin A	Homo sapiens	13-17
26503655-6	2016	Additionally, the anti-HIV activity and the rate of CatA hydrolysis showed good correlation within a large set of TFV phosphonoamidate prodrugs.	phosphonoamidate	118-134	cathepsin A	Homo sapiens	52-56
26503655-7	2016	The covalent hepatitis C virus (HCV) protease inhibitors (PIs) telaprevir and boceprevir potently inhibited CatA-mediated TAF activation (50% inhibitory concentration [IC50] = 0.27 and 0.16 muM, respectively) in vitro and also reduced its anti-HIV activity in primary human CD4(+) T lymphocytes (21- and 3-fold, respectively) at pharmacologically relevant concentrations.	telaprevir	63-73	cathepsin A	Homo sapiens	108-112
26503655-7	2016	The covalent hepatitis C virus (HCV) protease inhibitors (PIs) telaprevir and boceprevir potently inhibited CatA-mediated TAF activation (50% inhibitory concentration [IC50] = 0.27 and 0.16 muM, respectively) in vitro and also reduced its anti-HIV activity in primary human CD4(+) T lymphocytes (21- and 3-fold, respectively) at pharmacologically relevant concentrations.	N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide	78-88	cathepsin A	Homo sapiens	108-112
25801998-6	2015	Objective bibliometric analysis of CTSA-supported MTTs with positive growth in process scores showed that these teams tended to have enhanced scientific outcomes and published in new scientific domains, indicating the conduct of innovative science.	Monooxyethylene trimethylolpropane tristearate	50-54	cathepsin A	Homo sapiens	35-39
25917957-7	2015	SC-GSL enriched liposomes containing doxorubicin (Dox) were incubated at 4 C and 37 C and intracellular drug uptake was studied in comparison to standard liposomes and free Dox.	Doxorubicin	37-48	cathepsin A	Homo sapiens	3-6
26130766-1	2015	Lyso-glycosphingolipids (lyso-GSLs), the N-deacylated forms of glycosphingolipids (GSLs), are important synthetic intermediates for the preparation of GSL analogs.	lyso-glycosphingolipids	0-23	cathepsin A	Homo sapiens	30-33
26130766-1	2015	Lyso-glycosphingolipids (lyso-GSLs), the N-deacylated forms of glycosphingolipids (GSLs), are important synthetic intermediates for the preparation of GSL analogs.	Nitrogen	41-42	cathepsin A	Homo sapiens	30-33
26130766-1	2015	Lyso-glycosphingolipids (lyso-GSLs), the N-deacylated forms of glycosphingolipids (GSLs), are important synthetic intermediates for the preparation of GSL analogs.	Glycosphingolipids	5-23	cathepsin A	Homo sapiens	30-33
25917957-7	2015	SC-GSL enriched liposomes containing doxorubicin (Dox) were incubated at 4 C and 37 C and intracellular drug uptake was studied in comparison to standard liposomes and free Dox.	Doxorubicin	50-53	cathepsin A	Homo sapiens	3-6
25917957-9	2015	The transfer of SC-GSL was tumor cell-specific and induced membrane rearrangement as evidenced by a transbilayer flip-flop of pyrene-SM.	pyrene-sm	126-135	cathepsin A	Homo sapiens	19-22
25715344-6	2015	LacCer, the precursor of all GlcCer-related GSL, was significantly reduced only in BG1 cells treated with PPMP.	Glucosylceramides	29-35	cathepsin A	Homo sapiens	44-47
26212272-5	2015	RESULTS: Glycans were released from GSL standards comprising of ganglio-, asialo-ganglio- and the relatively resistant globo-series glycans, using as little as 1 mU of enzyme and 2 microg of GSL.	Polysaccharides	9-16	cathepsin A	Homo sapiens	36-39
26212272-5	2015	RESULTS: Glycans were released from GSL standards comprising of ganglio-, asialo-ganglio- and the relatively resistant globo-series glycans, using as little as 1 mU of enzyme and 2 microg of GSL.	Polysaccharides	9-16	cathepsin A	Homo sapiens	191-194
26212272-5	2015	RESULTS: Glycans were released from GSL standards comprising of ganglio-, asialo-ganglio- and the relatively resistant globo-series glycans, using as little as 1 mU of enzyme and 2 microg of GSL.	Polysaccharides	132-139	cathepsin A	Homo sapiens	36-39
26212272-8	2015	CONCLUSION: We describe a relatively simple, detergent-free, enzymatic release of glycans from PVDF-immobilized GSLs, followed by the detailed structural analysis afforded by PGC-LC-ESI-MS/MS, to offer a versatile method for the analysis of tumour and cell-derived GSL-glycans.	Polysaccharides	82-89	cathepsin A	Homo sapiens	112-115
26212272-8	2015	CONCLUSION: We describe a relatively simple, detergent-free, enzymatic release of glycans from PVDF-immobilized GSLs, followed by the detailed structural analysis afforded by PGC-LC-ESI-MS/MS, to offer a versatile method for the analysis of tumour and cell-derived GSL-glycans.	polyvinylidene fluoride	95-99	cathepsin A	Homo sapiens	112-115
25715344-6	2015	LacCer, the precursor of all GlcCer-related GSL, was significantly reduced only in BG1 cells treated with PPMP.	4-propionyloxy-4-phenyl-N-methylpiperidine	106-110	cathepsin A	Homo sapiens	44-47
25408353-1	2015	glycosyltransferase (GSL: GLTs) genes involved in SA-LeX and related GSLs biosynthesis in carcinoma cells by Biosimilar apoptotic agents: potential anticancer drugs.	2-chloro-10-(4'(N-beta-hydroxyethyl)piperazinyl-1')acetylphenothiazine	50-52	cathepsin A	Homo sapiens	21-24
25498019-12	2015	The GSL profiling of breast cancer cells showed fucosyltransferase 1 contributed to the biosynthesis of Globo-H and Fuc-LacCer.	fuc-laccer	116-126	cathepsin A	Homo sapiens	4-7
26609196-7	2015	These observations suggest that the very long fatty acid chains of ceramide are critical for GSL-mediated outside-in signaling.	Fatty Acids	46-56	cathepsin A	Homo sapiens	93-96
25553454-2	2015	GSLs cluster with cholesterol in cell membranes to form GSL-enriched lipid rafts.	Cholesterol	18-29	cathepsin A	Homo sapiens	0-3
26609196-7	2015	These observations suggest that the very long fatty acid chains of ceramide are critical for GSL-mediated outside-in signaling.	Ceramides	67-75	cathepsin A	Homo sapiens	93-96
24170324-8	2014	The cell-free extract of E. coli VL8 containing the reductase enzyme was able to reduce both the GSL glucoraphanin and its hydrolysis product sulforaphane to glucoerucin and erucin/erucin NIT, respectively.	glucoerucin	158-169	cathepsin A	Homo sapiens	97-100
24170324-8	2014	The cell-free extract of E. coli VL8 containing the reductase enzyme was able to reduce both the GSL glucoraphanin and its hydrolysis product sulforaphane to glucoerucin and erucin/erucin NIT, respectively.	sulforaphane	142-154	cathepsin A	Homo sapiens	97-100
24447064-4	2014	In addition to in vitro inhibition of the serine hydrolases ABHD10 and ACOT1/2, the most potent beta-lactone enantiomer was also found to inhibit these enzymes, as well as the serine peptidases CTSA and SCPEP1, in PC3 cells.	beta-Lactone	96-108	cathepsin A	Homo sapiens	194-198
23906628-1	2013	Glycosphingolipids (GSLs) are neoplastic and normal/cancer stem cell markers and GSL/cholesterol-containing membrane rafts are increased in cancer cell plasma membranes.	Glycosphingolipids	0-18	cathepsin A	Homo sapiens	20-23
24439373-5	2014	In studies with neonatal mice lacking access to bacterial sphingolipids, we found that treatment with B. fragilis glycosphingolipids-exemplified by an isolated peak (MW = 717.6) called GSL-Bf717-reduces colonic iNKT cell numbers and confers protection against oxazolone-induced colitis in adulthood.	Sphingolipids	58-71	cathepsin A	Homo sapiens	185-188
24439373-5	2014	In studies with neonatal mice lacking access to bacterial sphingolipids, we found that treatment with B. fragilis glycosphingolipids-exemplified by an isolated peak (MW = 717.6) called GSL-Bf717-reduces colonic iNKT cell numbers and confers protection against oxazolone-induced colitis in adulthood.	Oxazolone	260-269	cathepsin A	Homo sapiens	185-188
24463447-8	2014	Inhibition of GSL biosynthesis in vitro with a clinically approved inhibitor (N-butyldeoxynojirimycin) normalized GSL metabolism, corrected CD4+ T cell signaling and functional defects, and decreased anti-dsDNA antibody production by autologous B cells in SLE patients.	miglustat	78-101	cathepsin A	Homo sapiens	14-17
24463447-8	2014	Inhibition of GSL biosynthesis in vitro with a clinically approved inhibitor (N-butyldeoxynojirimycin) normalized GSL metabolism, corrected CD4+ T cell signaling and functional defects, and decreased anti-dsDNA antibody production by autologous B cells in SLE patients.	miglustat	78-101	cathepsin A	Homo sapiens	114-117
24199587-0	2014	In quest of strong Be-Ng bonds among the neutral Ng-Be complexes.	Beryllium	19-21	cathepsin A	Homo sapiens	49-54
25151392-2	2014	Each GSL contains a complex carbohydrate chain linked to a ceramide moiety that anchors the molecule to biomembranes.	Carbohydrates	28-40	cathepsin A	Homo sapiens	5-8
25151392-2	2014	Each GSL contains a complex carbohydrate chain linked to a ceramide moiety that anchors the molecule to biomembranes.	Ceramides	59-67	cathepsin A	Homo sapiens	5-8
25230230-5	2014	In our previous study using comparative molecular docking approach, it was concluded that [4-(Propan-2-yl) Phenyl]Carbamic acid (PPCA) may serve as a potential inhibitor.	[4-(propan-2-yl) phenyl]carbamic acid	90-127	cathepsin A	Homo sapiens	129-133
23906628-3	2013	The GSL-cholesterol complex reorients GSL carbohydrate to a membrane parallel, rather than perpendicular conformation, largely unavailable for antibody recognition.	Cholesterol	8-19	cathepsin A	Homo sapiens	4-7
23906628-3	2013	The GSL-cholesterol complex reorients GSL carbohydrate to a membrane parallel, rather than perpendicular conformation, largely unavailable for antibody recognition.	Cholesterol	8-19	cathepsin A	Homo sapiens	38-41
23906628-5	2013	In ovarian carcinoma, globotriaosyl ceramide (Gb3), the GSL receptor for the antineoplastic Escherichia coli-derived verotoxin, was increased throughout the tumor.	globotriaosylceramide	22-44	cathepsin A	Homo sapiens	56-59
23906628-10	2013	Within the GSL-cholesterol complex, filipin-cholesterol binding was also reduced.	Cholesterol	15-26	cathepsin A	Homo sapiens	11-14
23906628-10	2013	Within the GSL-cholesterol complex, filipin-cholesterol binding was also reduced.	Cholesterol	44-55	cathepsin A	Homo sapiens	11-14
23906628-13	2013	Lowering tumor membrane cholesterol may permit immune recognition of otherwise unavailable tumor-associated GSL carbohydrate, for more effective immunosurveillance and active/passive immunotherapy.	Cholesterol	24-35	cathepsin A	Homo sapiens	108-111
23456206-1	2013	Many pathogens target glycosphingolipids (GSLs), which, together with cholesterol, GPI-anchored proteins, and various signaling molecules, cluster on host cell membranes to form GSL-enriched membrane microdomains (lipid rafts).	Glycosphingolipids	22-40	cathepsin A	Homo sapiens	42-45
23861790-6	2013	The error for the 2-charge PPCA is found to be on average 23% smaller than that of optimally placed point dipole approximation, and comparable to that of the point quadrupole approximation.	dipole	106-112	cathepsin A	Homo sapiens	27-31
23456206-1	2013	Many pathogens target glycosphingolipids (GSLs), which, together with cholesterol, GPI-anchored proteins, and various signaling molecules, cluster on host cell membranes to form GSL-enriched membrane microdomains (lipid rafts).	Cholesterol	70-81	cathepsin A	Homo sapiens	42-45
23456206-6	2013	The GSL lactosylceramide (LacCer, CDw17), which binds to various microorganisms, including Candida albicans, is expressed predominantly on the plasma membranes of human mature neutrophils and forms membrane microdomains together with the Src family tyrosine kinase Lyn.	CDw17 antigen	8-24	cathepsin A	Homo sapiens	4-7
23456206-6	2013	The GSL lactosylceramide (LacCer, CDw17), which binds to various microorganisms, including Candida albicans, is expressed predominantly on the plasma membranes of human mature neutrophils and forms membrane microdomains together with the Src family tyrosine kinase Lyn.	CDw17 antigen	26-32	cathepsin A	Homo sapiens	4-7
22861813-0	2012	Novel beta-amino acid derivatives as inhibitors of cathepsin A.	beta-amino acid	6-21	cathepsin A	Homo sapiens	51-62
23601336-8	2013	PA among adults was associated with higher income and education, older age, presence of chronic conditions, and living within 100 miles of four specific CTSA locations.	Protactinium	0-2	cathepsin A	Homo sapiens	153-157
22985027-3	2012	Natural GSL compounds arglabin, an anticancer clinical drug, and micheliolide (MCL), are able to reduce the proportion of AML stem cells (CD34+CD38-) in primary AML cells.	arglabin	22-30	cathepsin A	Homo sapiens	8-11
22985027-3	2012	Natural GSL compounds arglabin, an anticancer clinical drug, and micheliolide (MCL), are able to reduce the proportion of AML stem cells (CD34+CD38-) in primary AML cells.	micheliolide	65-77	cathepsin A	Homo sapiens	8-11
22958137-8	2012	Further, degradation of the desulfo-GSL results in the release of d-thioglucose and the corresponding nitrile.	d-thioglucose	66-79	cathepsin A	Homo sapiens	36-39
22958137-8	2012	Further, degradation of the desulfo-GSL results in the release of d-thioglucose and the corresponding nitrile.	Nitriles	102-109	cathepsin A	Homo sapiens	36-39
22958137-9	2012	Iron(II) ions and plant matrix influence the thermal stability of the GSL and favor the formation of nitriles.	ammonium ferrous sulfate	0-8	cathepsin A	Homo sapiens	70-73
22958137-9	2012	Iron(II) ions and plant matrix influence the thermal stability of the GSL and favor the formation of nitriles.	Nitriles	101-109	cathepsin A	Homo sapiens	70-73
23099666-1	2012	PpcA is a small protein with 71 residues that contains three covalently bound hemes.	Heme	78-83	cathepsin A	Homo sapiens	0-4
22861813-4	2012	Pharmacological inhibition of CatA by the natural product ebelactone B increased renal bradykinin levels and prevented the development of salt-induced hypertension.	ebelactone B	58-70	cathepsin A	Homo sapiens	30-34
22861813-4	2012	Pharmacological inhibition of CatA by the natural product ebelactone B increased renal bradykinin levels and prevented the development of salt-induced hypertension.	Salts	138-142	cathepsin A	Homo sapiens	30-34
22861813-6	2012	In our work we identified novel beta-amino acid derivatives as inhibitors of CatA after a HTS analysis based on a project adapted fragment approach.	beta-amino acid	32-47	cathepsin A	Homo sapiens	77-81
22411838-4	2012	The results showed that AML patients had higher expression of the GSL lactotriaosylceramide (Lc3), GM3 and neolactotetraosylceramide (nLc4) in their bone marrow than did the healthy donors (P < 0.05), especially the M1 subtype of AML.	lactotriaosylceramide	70-91	cathepsin A	Homo sapiens	66-69
22102144-6	2012	Derivatization of the free amino group of a typical lyso-GSL, lyso-G(M1), with a prototype linker assembled from succinimidyl-[(N-maleimidopropionamido)-diethyleneglycol] ester and 2-mercaptoethylamine, was also tested.	lyso	52-56	cathepsin A	Homo sapiens	57-60
22583429-4	2012	To aid characterizing new drug candidates, a molecular docking study of catecholamines and a novel hypothetical compound [4-(propan-2-yl) phenyl]carbamic acid (PPCA) with TH is described.	Catecholamines	72-86	cathepsin A	Homo sapiens	160-164
22583429-4	2012	To aid characterizing new drug candidates, a molecular docking study of catecholamines and a novel hypothetical compound [4-(propan-2-yl) phenyl]carbamic acid (PPCA) with TH is described.	[4-(propan-2-yl) phenyl]carbamic acid	121-158	cathepsin A	Homo sapiens	160-164
22583429-7	2012	Our results corroborated a "hexa interacting amino acids unit" located in this deep narrow groove crucial to the interaction of PPCA and the studied catecholamines with TH, whereby the "His361-His336 dyad" was found to be even more crucial to these binding interactions.	Catecholamines	149-163	cathepsin A	Homo sapiens	128-132
24957371-4	2012	Although GSL structures can be assigned to only a few series with a common carbohydrate core, their structural variety and the complex pattern are challenges for their elucidation and quantification by mass spectrometric techniques.	Carbohydrates	75-87	cathepsin A	Homo sapiens	9-12
21549856-2	2011	As part of the investigation of the vertebrate glycosphingolipidome, GSL analysis is undergoing rapid expansion owing to the application of novel mass spectrometry techniques acting as the linchpin in the network of collaborations challenged to unravel structural and functional aspects of GSLs.	Glycosphingolipids	290-294	cathepsin A	Homo sapiens	69-72
21956927-6	2011	The most prominent GSL identified by the MALDI-MS and MS/MS analysis was Gb(4) Ceramide, with no appreciable amount of stage-specific embryonic antigens 3 or 4, or GD3, in endodermal cells.	gb(4) ceramide	73-87	cathepsin A	Homo sapiens	19-22
21549856-4	2011	The ceramide variability caused by the diversity of the long-chain amino alcohol and the fatty acid, which both may vary in chain length, degree of unsaturation, and type and number of substituents, further contributes to the increasing number of possible GSL species.	Ceramides	4-12	cathepsin A	Homo sapiens	256-259
21549856-4	2011	The ceramide variability caused by the diversity of the long-chain amino alcohol and the fatty acid, which both may vary in chain length, degree of unsaturation, and type and number of substituents, further contributes to the increasing number of possible GSL species.	Amino Alcohols	67-80	cathepsin A	Homo sapiens	256-259
21549856-4	2011	The ceramide variability caused by the diversity of the long-chain amino alcohol and the fatty acid, which both may vary in chain length, degree of unsaturation, and type and number of substituents, further contributes to the increasing number of possible GSL species.	Fatty Acids	89-99	cathepsin A	Homo sapiens	256-259
21600932-5	2011	The metabolism to the active 5"-triphosphate involves hydrolysis of the carboxyl ester by cathepsin A (Cat A) and carboxylesterase 1 (CES1) followed by a putative nucleophilic attack on the phosphorus by the carboxyl group resulting in the elimination of phenol and the alaninyl phosphate metabolite, PSI-353131.	5"-triphosphate	29-44	cathepsin A	Homo sapiens	90-101
21600932-5	2011	The metabolism to the active 5"-triphosphate involves hydrolysis of the carboxyl ester by cathepsin A (Cat A) and carboxylesterase 1 (CES1) followed by a putative nucleophilic attack on the phosphorus by the carboxyl group resulting in the elimination of phenol and the alaninyl phosphate metabolite, PSI-353131.	carboxyl ester	72-86	cathepsin A	Homo sapiens	90-101
21600932-5	2011	The metabolism to the active 5"-triphosphate involves hydrolysis of the carboxyl ester by cathepsin A (Cat A) and carboxylesterase 1 (CES1) followed by a putative nucleophilic attack on the phosphorus by the carboxyl group resulting in the elimination of phenol and the alaninyl phosphate metabolite, PSI-353131.	Phosphorus	190-200	cathepsin A	Homo sapiens	90-101
21600932-5	2011	The metabolism to the active 5"-triphosphate involves hydrolysis of the carboxyl ester by cathepsin A (Cat A) and carboxylesterase 1 (CES1) followed by a putative nucleophilic attack on the phosphorus by the carboxyl group resulting in the elimination of phenol and the alaninyl phosphate metabolite, PSI-353131.	Phenol	255-261	cathepsin A	Homo sapiens	90-101
21600932-5	2011	The metabolism to the active 5"-triphosphate involves hydrolysis of the carboxyl ester by cathepsin A (Cat A) and carboxylesterase 1 (CES1) followed by a putative nucleophilic attack on the phosphorus by the carboxyl group resulting in the elimination of phenol and the alaninyl phosphate metabolite, PSI-353131.	alaninyl phosphate	270-288	cathepsin A	Homo sapiens	90-101
21364033-8	2011	In cell lysates, bortezomib, but not carfilzomib, significantly inhibited the serine proteases cathepsin G (CatG), cathepsin A, chymase, dipeptidyl peptidase II, and HtrA2/Omi at potencies near or equivalent to that for the proteasome.	Bortezomib	17-27	cathepsin A	Homo sapiens	115-135
21396938-3	2011	Sequence alignments of GSL-binding proteins against the GBM of alpha-synuclein allowed the establishment of a consensus GBM sequence defined as K/H/R/-X(1-4)-Y/F-X(4-5)-K/H/R, where at least one of the X(1-4) residues is glycine.	Glycine	221-228	cathepsin A	Homo sapiens	23-26
21396938-5	2011	Surface pressure measurements of GSL monolayers at the air-water interface allowed us to determine the following order for alpha-synuclein-GSL interactions: GM3>Gb3>GalCer-NFA>GM1>sulfatide>GalCer-HFA>LacCer>GM4>GM2>asialo-GM1>GD3, indicating a marked preference for GSLs with one, three, or five sugar units.	gm3	157-160	cathepsin A	Homo sapiens	33-36
21396938-5	2011	Surface pressure measurements of GSL monolayers at the air-water interface allowed us to determine the following order for alpha-synuclein-GSL interactions: GM3>Gb3>GalCer-NFA>GM1>sulfatide>GalCer-HFA>LacCer>GM4>GM2>asialo-GM1>GD3, indicating a marked preference for GSLs with one, three, or five sugar units.	gm3	157-160	cathepsin A	Homo sapiens	139-142
20801890-4	2010	The first step, hydrolysis of the carboxyl ester by human cathepsin A (CatA) and/or carboxylesterase 1 (CES1), is a stereospecific reaction.	carboxyl ester	34-48	cathepsin A	Homo sapiens	58-69
21526484-3	2011	Cathepsin A of aneurysm parietal thrombus homogenate and blood clot homogenate showed the highest activity on Z-Phe-Ala.	N-benzyloxycarbonylphenylalanylalanine	110-119	cathepsin A	Homo sapiens	0-11
21383096-9	2011	Together, these observations indicate that the conversion of GS-9191 to cPrPMEDAP occurs in lysosomes via CatA-mediated ester cleavage, followed by the release of cPrPMEDAP, most likely through the combination of enzyme-driven and spontaneous pH-driven hydrolysis of a cPrPMEDAP-Phe intermediate.	N(6)-cyclopropyl-9-(2-phosphonylmethoxyethyl)-2,6-diaminopurine	72-81	cathepsin A	Homo sapiens	106-110
21383096-9	2011	Together, these observations indicate that the conversion of GS-9191 to cPrPMEDAP occurs in lysosomes via CatA-mediated ester cleavage, followed by the release of cPrPMEDAP, most likely through the combination of enzyme-driven and spontaneous pH-driven hydrolysis of a cPrPMEDAP-Phe intermediate.	Esters	120-125	cathepsin A	Homo sapiens	106-110
20716521-2	2010	Lipid-based "aglycone" interactions can influence GSL carbohydrate epitope presentation.	CHEBI:166892	13-21	cathepsin A	Homo sapiens	50-53
20716521-3	2010	To evaluate this relationship, Verotoxin binding its receptor GSL, globotriaosyl ceramide (Gb(3)), was analyzed in simple GSL/cholesterol, detergent-resistant membrane vesicles by equilibrium density gradient centrifugation.	globotriaosylceramide	67-89	cathepsin A	Homo sapiens	62-65
20716521-3	2010	To evaluate this relationship, Verotoxin binding its receptor GSL, globotriaosyl ceramide (Gb(3)), was analyzed in simple GSL/cholesterol, detergent-resistant membrane vesicles by equilibrium density gradient centrifugation.	globotriaosylceramide	91-96	cathepsin A	Homo sapiens	62-65
20716521-8	2010	This appears to be a general GSL-cholesterol property, because similar receptor-inactive vesicles were separated for other GSL-protein ligand systems; cholera toxin (CTx)-GM1, HIVgp120-galactosyl ceramide/sulfatide.	Cholesterol	33-44	cathepsin A	Homo sapiens	29-32
20716521-10	2010	We found GalCer and GlcCer bind Gb(3), suggesting GSL-GSL interaction can counter cholesterol masking of Gb(3).	globotriaosylceramide	32-37	cathepsin A	Homo sapiens	50-53
20716521-10	2010	We found GalCer and GlcCer bind Gb(3), suggesting GSL-GSL interaction can counter cholesterol masking of Gb(3).	globotriaosylceramide	32-37	cathepsin A	Homo sapiens	54-57
20716521-10	2010	We found GalCer and GlcCer bind Gb(3), suggesting GSL-GSL interaction can counter cholesterol masking of Gb(3).	Cholesterol	82-93	cathepsin A	Homo sapiens	50-53
20716521-10	2010	We found GalCer and GlcCer bind Gb(3), suggesting GSL-GSL interaction can counter cholesterol masking of Gb(3).	Cholesterol	82-93	cathepsin A	Homo sapiens	54-57
20716521-10	2010	We found GalCer and GlcCer bind Gb(3), suggesting GSL-GSL interaction can counter cholesterol masking of Gb(3).	globotriaosylceramide	105-110	cathepsin A	Homo sapiens	50-53
20716521-10	2010	We found GalCer and GlcCer bind Gb(3), suggesting GSL-GSL interaction can counter cholesterol masking of Gb(3).	globotriaosylceramide	105-110	cathepsin A	Homo sapiens	54-57
20716521-12	2010	Cell membrane GSL masking was cholesterol- and actin-dependent.	Cholesterol	30-41	cathepsin A	Homo sapiens	14-17
20716521-15	2010	Cholesterol masking of most cell membrane GSLs may impinge many GSL receptor functions.	Cholesterol	0-11	cathepsin A	Homo sapiens	42-45
20801890-4	2010	The first step, hydrolysis of the carboxyl ester by human cathepsin A (CatA) and/or carboxylesterase 1 (CES1), is a stereospecific reaction.	carboxyl ester	34-48	cathepsin A	Homo sapiens	71-75
20801890-7	2010	Studies with inhibitors of CatA and/or CES1 indicated that CatA is primarily responsible for hydrolysis of the carboxyl ester in clone A cells, although in primary human hepatocytes, both CatA and CES1 contribute to the hydrolysis.	carboxyl ester	111-125	cathepsin A	Homo sapiens	27-31
20801890-7	2010	Studies with inhibitors of CatA and/or CES1 indicated that CatA is primarily responsible for hydrolysis of the carboxyl ester in clone A cells, although in primary human hepatocytes, both CatA and CES1 contribute to the hydrolysis.	carboxyl ester	111-125	cathepsin A	Homo sapiens	59-63
20801890-7	2010	Studies with inhibitors of CatA and/or CES1 indicated that CatA is primarily responsible for hydrolysis of the carboxyl ester in clone A cells, although in primary human hepatocytes, both CatA and CES1 contribute to the hydrolysis.	carboxyl ester	111-125	cathepsin A	Homo sapiens	59-63
20957119-8	2010	Specifically, high concentrations of chromium throughout GSL correspond to an average similarity of chromium resistance genes that is 22% higher than taxonomic similarity.	Chromium	37-45	cathepsin A	Homo sapiens	57-60
21044592-2	2010	Owing to the importance of glycosphingolipids (GSLs) in modulating structure and function of membranes and membrane proteins, methods to tune the GSL content in SLBs would be desirable.	Glycosphingolipids	27-45	cathepsin A	Homo sapiens	47-50
20624608-0	2010	Terpioside B, a difucosyl GSL from the marine sponge Terpios sp.	terpioside B	0-12	cathepsin A	Homo sapiens	26-29
20624608-0	2010	Terpioside B, a difucosyl GSL from the marine sponge Terpios sp.	terpios sp	53-63	cathepsin A	Homo sapiens	26-29
20213676-5	2010	The combined method works on microgram scale of GSL mixtures and is advantageous in that it omits laborious and time-consuming GSL extraction from the silica gel layer.	Silicon Dioxide	151-157	cathepsin A	Homo sapiens	127-130
20213680-4	2010	The GSL structure is characterized by two entities: a hydrophilic glycan and a hydrophobic ceramide moiety.	Polysaccharides	66-72	cathepsin A	Homo sapiens	4-7
20213680-4	2010	The GSL structure is characterized by two entities: a hydrophilic glycan and a hydrophobic ceramide moiety.	Ceramides	91-99	cathepsin A	Homo sapiens	4-7
20140095-6	2010	Cholesterol inhibited the interaction of Abeta(1-40) with HFA-GSLs, through dilution of the GSL in the monolayer, but rendered the initially inactive NFA-GSLs competent for Abeta(1-40) binding.	Cholesterol	0-11	cathepsin A	Homo sapiens	62-65
20140095-7	2010	Both crystallographic data and molecular dynamics simulations suggested that the active conformation of HFA-GSL involves a H-bond network that restricts the orientation of the sugar group of GSLs in a parallel orientation with respect to the membrane.	Sugars	176-181	cathepsin A	Homo sapiens	108-111
20140095-7	2010	Both crystallographic data and molecular dynamics simulations suggested that the active conformation of HFA-GSL involves a H-bond network that restricts the orientation of the sugar group of GSLs in a parallel orientation with respect to the membrane.	Glycosphingolipids	191-195	cathepsin A	Homo sapiens	108-111
19714866-9	2009	The loss of catalytic activity caused by the deletion of the second N-glycan was rescued by increasing PPCA expression.	n-glycan	68-76	cathepsin A	Homo sapiens	103-107
19517226-3	2009	Based on the molecular screening model using p-nitrophenyl phosphate (p-NPP) as a substrate for preliminary screening and (32)P-labeled 19-residue phosphopeptide as a specific substrate for final determination, we found that the total ginsenoside extracts from stems and leaves of Panax ginseng (GSL) could enhance the phosphatase activity of purified CN.	Ginsenosides	235-246	cathepsin A	Homo sapiens	296-299
19517226-5	2009	Pretreatment of the cells with GSL prior to CsA exposure could alleviate CsA-induced CN inhibition and tau hyperphosphorylation to some degree.	Cyclosporine	44-47	cathepsin A	Homo sapiens	31-34
19517226-5	2009	Pretreatment of the cells with GSL prior to CsA exposure could alleviate CsA-induced CN inhibition and tau hyperphosphorylation to some degree.	Cyclosporine	73-76	cathepsin A	Homo sapiens	31-34
19517226-7	2009	It is speculated that GSL weakens CsA-induced CN inhibition through the antioxidant mechanisms.	Cyclosporine	34-37	cathepsin A	Homo sapiens	22-25
19908908-3	2009	Specific staining was achieved by means of primary anti-GSL antibodies, directed against lactosylceramide, globotriaosylceramide, and globotetraosylceramide, in conjunction with alkaline phosphatase (AP)- or horseradish peroxidase (HRP)-conjugated secondary antibodies together with the appropriate chromogenic substrates.	CDw17 antigen	89-105	cathepsin A	Homo sapiens	56-59
19781539-2	2010	Variation in GSL fatty acid composition may mediate aglycone regulation of GSL membrane receptor function by a differential interaction with cholesterol and other membrane components which may be differentially organized within plasma membrane lipid domains.	Cholesterol	141-152	cathepsin A	Homo sapiens	13-16
19781539-2	2010	Variation in GSL fatty acid composition may mediate aglycone regulation of GSL membrane receptor function by a differential interaction with cholesterol and other membrane components which may be differentially organized within plasma membrane lipid domains.	Cholesterol	141-152	cathepsin A	Homo sapiens	75-78
19683044-2	2009	AIMS OF THE STUDY: The purpose of the present study is to determine whether the ethanol (EtOH) extract of GSL regulates the inflammatory reaction stimulated by phorbol-12-myristate 13-acetate plus calcium ionophore A23187 (PMACI) in human mast cells (HMC-1).	Ethanol	80-87	cathepsin A	Homo sapiens	106-109
19683044-2	2009	AIMS OF THE STUDY: The purpose of the present study is to determine whether the ethanol (EtOH) extract of GSL regulates the inflammatory reaction stimulated by phorbol-12-myristate 13-acetate plus calcium ionophore A23187 (PMACI) in human mast cells (HMC-1).	Ethanol	89-93	cathepsin A	Homo sapiens	106-109
19683044-2	2009	AIMS OF THE STUDY: The purpose of the present study is to determine whether the ethanol (EtOH) extract of GSL regulates the inflammatory reaction stimulated by phorbol-12-myristate 13-acetate plus calcium ionophore A23187 (PMACI) in human mast cells (HMC-1).	Tetradecanoylphorbol Acetate	160-191	cathepsin A	Homo sapiens	106-109
19683044-2	2009	AIMS OF THE STUDY: The purpose of the present study is to determine whether the ethanol (EtOH) extract of GSL regulates the inflammatory reaction stimulated by phorbol-12-myristate 13-acetate plus calcium ionophore A23187 (PMACI) in human mast cells (HMC-1).	Calcimycin	215-221	cathepsin A	Homo sapiens	106-109
19683044-2	2009	AIMS OF THE STUDY: The purpose of the present study is to determine whether the ethanol (EtOH) extract of GSL regulates the inflammatory reaction stimulated by phorbol-12-myristate 13-acetate plus calcium ionophore A23187 (PMACI) in human mast cells (HMC-1).	pmaci	223-228	cathepsin A	Homo sapiens	106-109
19683044-6	2009	RESULTS: EtOH extract of GSL (EGS) inhibits the expression of extracellular signal-regulated kinase (ERK), one of a MAPK, nuclear transcription factors involving nuclear factor (NF)-kappaB and Activator protein (AP)-1, COX-2 and iNOS.	Ethanol	9-13	cathepsin A	Homo sapiens	25-28
19683044-6	2009	RESULTS: EtOH extract of GSL (EGS) inhibits the expression of extracellular signal-regulated kinase (ERK), one of a MAPK, nuclear transcription factors involving nuclear factor (NF)-kappaB and Activator protein (AP)-1, COX-2 and iNOS.	egs	30-33	cathepsin A	Homo sapiens	25-28
19714866-12	2009	The omission of the second N-glycan can be compensated for by upregulating the expression of PPCA.	n-glycan	27-35	cathepsin A	Homo sapiens	93-97
19066718-10	2009	Knockdown of PPCA in osteoclast precursors with PPCA siRNA stimulated binding of nuclear proteins to oligonucleotides containing an NF-kappaB binding motif and increased osteoclastogenesis.	Oligonucleotides	101-117	cathepsin A	Homo sapiens	13-17
19017528-5	2009	Transcription of SREBP target genes and cholesterol synthesis are also induced in the GSL-defective cells.	Cholesterol	40-51	cathepsin A	Homo sapiens	86-89
19017528-6	2009	These results indicate that GSL deficiency up-regulates the SREBP pathway, pointing out the regulatory role of GSL in cholesterol homeostasis.	Cholesterol	118-129	cathepsin A	Homo sapiens	28-31
18930085-3	2009	GSL-liposomes remarkably enhanced the production of IFN-gamma from splenocytes in vitro and this enhancement depended on the content of the pH-sensitive lipid dioleoyl-phosphoethanolamine (DOPE) in the liposomes.	dioleoyl phosphoethanolamine	159-187	cathepsin A	Homo sapiens	0-3
18930085-3	2009	GSL-liposomes remarkably enhanced the production of IFN-gamma from splenocytes in vitro and this enhancement depended on the content of the pH-sensitive lipid dioleoyl-phosphoethanolamine (DOPE) in the liposomes.	1,2-dielaidoylphosphatidylethanolamine	189-193	cathepsin A	Homo sapiens	0-3
18930085-4	2009	GSL-liposomes containing DOPE were clearly broken in late endosomes and this may facilitate effective loading of GSLs onto CD1 molecules.	Glycosphingolipids	113-117	cathepsin A	Homo sapiens	0-3
19066718-10	2009	Knockdown of PPCA in osteoclast precursors with PPCA siRNA stimulated binding of nuclear proteins to oligonucleotides containing an NF-kappaB binding motif and increased osteoclastogenesis.	Oligonucleotides	101-117	cathepsin A	Homo sapiens	48-52
19005060-6	2008	This reduction in the presence of small soluble oligomers resulted in reduced binding to lipid membranes and attenuated toxicity for the GSL peptides.	Peptides	141-149	cathepsin A	Homo sapiens	137-140
17626424-9	2007	Based on the data for GSL hydrolysis and ITC degradation, the concentration of ITC following GSL application was successfully modeled assuming complete conversion of glucosinolate to isothiocyanate and first-order degradation of isothiocyanate.	Glucosinolates	166-179	cathepsin A	Homo sapiens	93-96
18430788-7	2008	Results from the present study indicate that in addition to cathepsin A, a variety of serine and cysteine proteases cleave GS-7340 and other phosphonoamidate prodrugs of TFV.	phosphonoamidate	141-157	cathepsin A	Homo sapiens	60-71
17664528-10	2007	The alteration of neuraminidase and PPCA patterns in several of the Western blotting analyses performed on patient protein extracts indicated that the LMC is affected in at least some GM1-gangliosidosis and Morquio B patients.	LMC	151-154	cathepsin A	Homo sapiens	36-40
18034356-5	2008	By germinating the lines in a medium containing the nitric oxide (NO) donor, sodium nitroprusside (SNP), it was demonstrated that both GLB1 and GLB2 promote bolting by antagonizing the effect of NO, suggesting that non-symbiotic plant hemoglobin controls bolting by scavenging the floral transition signal molecule, NO.	Nitric Oxide	52-64	cathepsin A	Homo sapiens	144-148
18034356-5	2008	By germinating the lines in a medium containing the nitric oxide (NO) donor, sodium nitroprusside (SNP), it was demonstrated that both GLB1 and GLB2 promote bolting by antagonizing the effect of NO, suggesting that non-symbiotic plant hemoglobin controls bolting by scavenging the floral transition signal molecule, NO.	Nitroprusside	77-97	cathepsin A	Homo sapiens	144-148
17626424-9	2007	Based on the data for GSL hydrolysis and ITC degradation, the concentration of ITC following GSL application was successfully modeled assuming complete conversion of glucosinolate to isothiocyanate and first-order degradation of isothiocyanate.	isothiocyanic acid	183-197	cathepsin A	Homo sapiens	93-96
17626424-9	2007	Based on the data for GSL hydrolysis and ITC degradation, the concentration of ITC following GSL application was successfully modeled assuming complete conversion of glucosinolate to isothiocyanate and first-order degradation of isothiocyanate.	isothiocyanic acid	229-243	cathepsin A	Homo sapiens	93-96
17371832-4	2007	In this study, we show that a synthetic GSL with nonnatural stereochemistry, beta-D-lactosyl-N-octanoyl-L-threo-sphingosine, (1) selectively inhibits caveolar endocytosis and SV40 virus infection, (2) blocks the clustering of lipids and proteins into GSLs and cholesterol-enriched microdomains (rafts) at the PM, and (3) inhibits beta1-integrin activation and downstream signaling.	beta-d-lactosyl-n-octanoyl-l-threo-sphingosine	77-123	cathepsin A	Homo sapiens	40-43
17371832-4	2007	In this study, we show that a synthetic GSL with nonnatural stereochemistry, beta-D-lactosyl-N-octanoyl-L-threo-sphingosine, (1) selectively inhibits caveolar endocytosis and SV40 virus infection, (2) blocks the clustering of lipids and proteins into GSLs and cholesterol-enriched microdomains (rafts) at the PM, and (3) inhibits beta1-integrin activation and downstream signaling.	Glycosphingolipids	251-255	cathepsin A	Homo sapiens	40-43
17371832-4	2007	In this study, we show that a synthetic GSL with nonnatural stereochemistry, beta-D-lactosyl-N-octanoyl-L-threo-sphingosine, (1) selectively inhibits caveolar endocytosis and SV40 virus infection, (2) blocks the clustering of lipids and proteins into GSLs and cholesterol-enriched microdomains (rafts) at the PM, and (3) inhibits beta1-integrin activation and downstream signaling.	Cholesterol	260-271	cathepsin A	Homo sapiens	40-43
16906718-3	2006	A matrix solution of 2,5-dihydroxybenzoic acid (DHB) in acetonitrile/water (1:1 v/v) was then added directly to the unstained GSL spots, and the GSLs were directly analyzed by MALDI-QIT-TOF MS.	2,5-dihydroxybenzoic acid	21-46	cathepsin A	Homo sapiens	126-129
17215249-15	2007	These findings indicate that GSL, particularly GM2, forms a complex with CD82, and that such complex interacts with Met and thereby inhibits HGF-induced Met tyrosine kinase activity, as well as integrin to Met cross-talk.	gm2	47-50	cathepsin A	Homo sapiens	29-32
17145787-0	2007	Cathepsin A is the major hydrolase catalyzing the intracellular hydrolysis of the antiretroviral nucleotide phosphonoamidate prodrugs GS-7340 and GS-9131.	nucleotide phosphonoamidate	97-124	cathepsin A	Homo sapiens	0-11
17145787-5	2007	Recombinant CatA and the isolated prodrug hydrolase displayed identical susceptibilities to inhibitors and identical substrate preferences towards a panel of tenofovir phosphonoamidate prodrugs.	tenofovir phosphonoamidate	158-184	cathepsin A	Homo sapiens	12-16
17145787-8	2007	Collectively, these data demonstrate the key role of CatA in the intracellular activation of nucleotide phosphonoamidate prodrugs and open new possibilities for further improvement of this important class of antiviral prodrugs.	nucleotide phosphonoamidate	93-120	cathepsin A	Homo sapiens	53-57
17135452-5	2007	Only the GSL Pb-1 antigen, which presents the carbohydrate structure Galfbeta1-6(Manalpha1-3)Manbeta1, was reactive with the PCM patient sera.	Carbohydrates	46-58	cathepsin A	Homo sapiens	9-12
17088967-4	2006	The synthesis and structure of one such mixed-metal coordination polymer, Cu(PPCA)(2)HgI(2), is also presented.	Metals	46-51	cathepsin A	Homo sapiens	77-81
17088967-4	2006	The synthesis and structure of one such mixed-metal coordination polymer, Cu(PPCA)(2)HgI(2), is also presented.	Polymers	65-72	cathepsin A	Homo sapiens	77-81
16906718-3	2006	A matrix solution of 2,5-dihydroxybenzoic acid (DHB) in acetonitrile/water (1:1 v/v) was then added directly to the unstained GSL spots, and the GSLs were directly analyzed by MALDI-QIT-TOF MS.	2,5-dihydroxybenzoic acid	48-51	cathepsin A	Homo sapiens	126-129
16777057-2	2006	GLTP can catalyze the transfer of a fluorescently labeled GSL, anthrylvinyl-galactosylceramide (AV-GalCer), from vesicles composed of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine and dipalmitoylphosphatidylcholine matrices, but not from vesicles prepared from N-palmitoylsphingomyelin, regardless of the cholesterol content of the vesicles.	palmitoylsphingomyelin	264-288	cathepsin A	Homo sapiens	58-61
16777057-2	2006	GLTP can catalyze the transfer of a fluorescently labeled GSL, anthrylvinyl-galactosylceramide (AV-GalCer), from vesicles composed of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine and dipalmitoylphosphatidylcholine matrices, but not from vesicles prepared from N-palmitoylsphingomyelin, regardless of the cholesterol content of the vesicles.	Cholesterol	308-319	cathepsin A	Homo sapiens	58-61
16777057-2	2006	GLTP can catalyze the transfer of a fluorescently labeled GSL, anthrylvinyl-galactosylceramide (AV-GalCer), from vesicles composed of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine and dipalmitoylphosphatidylcholine matrices, but not from vesicles prepared from N-palmitoylsphingomyelin, regardless of the cholesterol content of the vesicles.	anthrylvinyl-galactosylceramide	63-94	cathepsin A	Homo sapiens	58-61
17072019-6	2006	In order to overcome some of these problems, we have synthesized adamantyl GSL analogs which, in part, mimic GSL membrane receptor function in solution.	adamantyl	65-74	cathepsin A	Homo sapiens	75-78
16777057-2	2006	GLTP can catalyze the transfer of a fluorescently labeled GSL, anthrylvinyl-galactosylceramide (AV-GalCer), from vesicles composed of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine and dipalmitoylphosphatidylcholine matrices, but not from vesicles prepared from N-palmitoylsphingomyelin, regardless of the cholesterol content of the vesicles.	av-galcer	96-105	cathepsin A	Homo sapiens	58-61
16777057-2	2006	GLTP can catalyze the transfer of a fluorescently labeled GSL, anthrylvinyl-galactosylceramide (AV-GalCer), from vesicles composed of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine and dipalmitoylphosphatidylcholine matrices, but not from vesicles prepared from N-palmitoylsphingomyelin, regardless of the cholesterol content of the vesicles.	1-palmitoyl-2-oleoylphosphatidylcholine	134-182	cathepsin A	Homo sapiens	58-61
16777057-2	2006	GLTP can catalyze the transfer of a fluorescently labeled GSL, anthrylvinyl-galactosylceramide (AV-GalCer), from vesicles composed of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine and dipalmitoylphosphatidylcholine matrices, but not from vesicles prepared from N-palmitoylsphingomyelin, regardless of the cholesterol content of the vesicles.	1,2-Dipalmitoylphosphatidylcholine	187-217	cathepsin A	Homo sapiens	58-61
17072019-6	2006	In order to overcome some of these problems, we have synthesized adamantyl GSL analogs which, in part, mimic GSL membrane receptor function in solution.	adamantyl	65-74	cathepsin A	Homo sapiens	109-112
17072019-11	2006	We are focused on two derivatives, adamantyl globotriaosyl ceramide and adamantyl sulfogalactosyl ceramide, and have used these analogs to probe GSL function in microbial pathology and hsp70 function.	adamantyl-globotriaosyl ceramide	35-67	cathepsin A	Homo sapiens	145-148
17072019-11	2006	We are focused on two derivatives, adamantyl globotriaosyl ceramide and adamantyl sulfogalactosyl ceramide, and have used these analogs to probe GSL function in microbial pathology and hsp70 function.	adamantyl sulfogalactosyl ceramide	72-106	cathepsin A	Homo sapiens	145-148
15080734-3	2004	The GSL species investigated were isomeric monosialogangliosides of the neolacto series from a ganglioside preparation of human granulocytes, the disialoganglioside GD3 from a human melanoma lipid extract, and ganglio series Gg3Cer of a neutral GSL preparation from murine lymphoreticular MDAY-D2 cells.	Gangliosides	52-63	cathepsin A	Homo sapiens	4-7
15668908-5	2005	The most common treatment strategies for these disorders involve plasmapheresis and the use of steroids for reducing anti-GSL antibody titers to ameliorate patients" clinical symptoms.	Steroids	95-103	cathepsin A	Homo sapiens	122-125
15668908-8	2005	In addition, anti-GSL antibodies, such as anti-GM1, may cause nerve dysfunction and injury by interfering with the ion channel function at the nodes of Ranvier, where carbohydrate epitopes of glycoconjugates are located.	G(M1) Ganglioside	47-50	cathepsin A	Homo sapiens	18-21
15668908-8	2005	In addition, anti-GSL antibodies, such as anti-GM1, may cause nerve dysfunction and injury by interfering with the ion channel function at the nodes of Ranvier, where carbohydrate epitopes of glycoconjugates are located.	Carbohydrates	167-179	cathepsin A	Homo sapiens	18-21
15207833-5	2004	Understanding the precise role of the endosomal-lysosomal system in the overall homeostatic control of GSL expression in neurons can be expected to provide key insight into both the function of gangliosides and the pathogenic mechanisms underlying lysosomal disease.	Gangliosides	194-206	cathepsin A	Homo sapiens	103-106
14687610-6	2004	The PPCA-overexpressing cell lines also retained the ability to differentiate bi-directionally as well as the parent cells; into neuronal cells on induction by dibutyryl cAMP in serum-free medium and into Schwannian cells on induction by bromodeoxyuridine.	Cyclic AMP	170-174	cathepsin A	Homo sapiens	4-8
14687610-6	2004	The PPCA-overexpressing cell lines also retained the ability to differentiate bi-directionally as well as the parent cells; into neuronal cells on induction by dibutyryl cAMP in serum-free medium and into Schwannian cells on induction by bromodeoxyuridine.	Bromodeoxyuridine	238-255	cathepsin A	Homo sapiens	4-8
15080734-5	2004	The resulting mass spectra show that only analytical quantities of approximately 1 microg of a single GSL within a complex mixture are required for the structure determination of immunostained GSLs by MS and MS/MS.	Glycosphingolipids	193-197	cathepsin A	Homo sapiens	102-105
14506277-3	2003	Here, we investigate the role of glycosphingolipids (GSLs) in raft structure and raft-mediated signal transduction in T lymphocytes by the usage of a specific GSL synthesis inhibitor, d-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-PDMP).	Glycosphingolipids	33-51	cathepsin A	Homo sapiens	53-56
14506277-3	2003	Here, we investigate the role of glycosphingolipids (GSLs) in raft structure and raft-mediated signal transduction in T lymphocytes by the usage of a specific GSL synthesis inhibitor, d-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (D-PDMP).	RV 538	184-240	cathepsin A	Homo sapiens	53-56
14506277-7	2003	Moreover, GPI-anchored proteins became more susceptible to phosphatidylinositol-specific phospholipase C cleavage in D-PDMP-treated cells, demonstrating that GSL depletion from rafts primarily influences the expression state and function of GPI-anchored proteins.	Phosphatidylinositols	59-79	cathepsin A	Homo sapiens	158-161
14506277-7	2003	Moreover, GPI-anchored proteins became more susceptible to phosphatidylinositol-specific phospholipase C cleavage in D-PDMP-treated cells, demonstrating that GSL depletion from rafts primarily influences the expression state and function of GPI-anchored proteins.	RV 538	117-123	cathepsin A	Homo sapiens	158-161
14506277-8	2003	Finally, by comparing the effect of D-PDMP with that of methyl-beta-cyclodextrin, we identified that compared with cholesterol depletion, GSL depletion has the opposite effect on the phosphatidylinositol-specific phospholipase C sensitivity and signaling ability of GPI-anchored proteins.	RV 538	36-42	cathepsin A	Homo sapiens	138-141
14506277-8	2003	Finally, by comparing the effect of D-PDMP with that of methyl-beta-cyclodextrin, we identified that compared with cholesterol depletion, GSL depletion has the opposite effect on the phosphatidylinositol-specific phospholipase C sensitivity and signaling ability of GPI-anchored proteins.	methyl-beta-cyclodextrin	56-80	cathepsin A	Homo sapiens	138-141
14506277-8	2003	Finally, by comparing the effect of D-PDMP with that of methyl-beta-cyclodextrin, we identified that compared with cholesterol depletion, GSL depletion has the opposite effect on the phosphatidylinositol-specific phospholipase C sensitivity and signaling ability of GPI-anchored proteins.	Phosphatidylinositols	183-203	cathepsin A	Homo sapiens	138-141
12576084-4	2003	The deamidase activity was inhibited by Ebelactone B and the serine protease inhibitor, phenylmethanesulfonyl fluoride (PMSF), while the degradation of the synthetic stereoisomer, Asn-Trp-Phe-NH(2) (N(l)WF-NH(2)), was sensitive to the divalent cation-chelating agent, o-phenanthroline, and aminopeptidase inhibitors, amastatin and bestatin.	ebelactone B	40-52	cathepsin A	Homo sapiens	4-13
12628483-6	2003	Because many GSL-binding pathogens have been shown to bind "multivalent" saccharides, approaches for identifying and preparing them as well as methods for characterizing their effectiveness as ligands are reviewed.	Carbohydrates	73-84	cathepsin A	Homo sapiens	13-16
12356333-1	2003	A 9.6 kDa periplasmic c -type cytochrome, designated PpcA, was purified from the Fe(III)-reducing bacterium Geobacter sulfurreducens and characterized.	ferric sulfate	81-88	cathepsin A	Homo sapiens	53-57
12356333-6	2003	When ppcA was expressed in trans, the full capacity for Fe(III) reduction with acetate was restored.	ferric sulfate	56-63	cathepsin A	Homo sapiens	5-9
12356333-6	2003	When ppcA was expressed in trans, the full capacity for Fe(III) reduction with acetate was restored.	Acetates	79-86	cathepsin A	Homo sapiens	5-9
12356333-8	2003	The rates of reduction of Fe(III), AQDS, U(VI) and fumarate were also the same in the wild type and ppcA mutant when hydrogen was supplied as the electron donor.	ferric sulfate	26-33	cathepsin A	Homo sapiens	100-104
12356333-8	2003	The rates of reduction of Fe(III), AQDS, U(VI) and fumarate were also the same in the wild type and ppcA mutant when hydrogen was supplied as the electron donor.	Fumarates	51-59	cathepsin A	Homo sapiens	100-104
12356333-8	2003	The rates of reduction of Fe(III), AQDS, U(VI) and fumarate were also the same in the wild type and ppcA mutant when hydrogen was supplied as the electron donor.	Hydrogen	117-125	cathepsin A	Homo sapiens	100-104
12356333-9	2003	When taken together with previous studies on other electron transport proteins in G. sulfurreducens, these results suggest that PpcA serves as an intermediary electron carrier from acetate to terminal Fe(III) reductases in the outer membrane, and is also involved in the transfer of electrons from acetate to U(VI) and humics.	Acetates	181-188	cathepsin A	Homo sapiens	128-132
12356333-9	2003	When taken together with previous studies on other electron transport proteins in G. sulfurreducens, these results suggest that PpcA serves as an intermediary electron carrier from acetate to terminal Fe(III) reductases in the outer membrane, and is also involved in the transfer of electrons from acetate to U(VI) and humics.	Acetates	298-305	cathepsin A	Homo sapiens	128-132
12576084-4	2003	The deamidase activity was inhibited by Ebelactone B and the serine protease inhibitor, phenylmethanesulfonyl fluoride (PMSF), while the degradation of the synthetic stereoisomer, Asn-Trp-Phe-NH(2) (N(l)WF-NH(2)), was sensitive to the divalent cation-chelating agent, o-phenanthroline, and aminopeptidase inhibitors, amastatin and bestatin.	Phenylmethylsulfonyl Fluoride	88-118	cathepsin A	Homo sapiens	4-13
12576084-4	2003	The deamidase activity was inhibited by Ebelactone B and the serine protease inhibitor, phenylmethanesulfonyl fluoride (PMSF), while the degradation of the synthetic stereoisomer, Asn-Trp-Phe-NH(2) (N(l)WF-NH(2)), was sensitive to the divalent cation-chelating agent, o-phenanthroline, and aminopeptidase inhibitors, amastatin and bestatin.	Phenylmethylsulfonyl Fluoride	120-124	cathepsin A	Homo sapiens	4-13
12576084-4	2003	The deamidase activity was inhibited by Ebelactone B and the serine protease inhibitor, phenylmethanesulfonyl fluoride (PMSF), while the degradation of the synthetic stereoisomer, Asn-Trp-Phe-NH(2) (N(l)WF-NH(2)), was sensitive to the divalent cation-chelating agent, o-phenanthroline, and aminopeptidase inhibitors, amastatin and bestatin.	asparaginyl-tryptophyl-phenylalaninamide	180-197	cathepsin A	Homo sapiens	4-13
12576084-4	2003	The deamidase activity was inhibited by Ebelactone B and the serine protease inhibitor, phenylmethanesulfonyl fluoride (PMSF), while the degradation of the synthetic stereoisomer, Asn-Trp-Phe-NH(2) (N(l)WF-NH(2)), was sensitive to the divalent cation-chelating agent, o-phenanthroline, and aminopeptidase inhibitors, amastatin and bestatin.	n(l)wf	199-205	cathepsin A	Homo sapiens	4-13
12576084-4	2003	The deamidase activity was inhibited by Ebelactone B and the serine protease inhibitor, phenylmethanesulfonyl fluoride (PMSF), while the degradation of the synthetic stereoisomer, Asn-Trp-Phe-NH(2) (N(l)WF-NH(2)), was sensitive to the divalent cation-chelating agent, o-phenanthroline, and aminopeptidase inhibitors, amastatin and bestatin.	1,10-phenanthroline	268-284	cathepsin A	Homo sapiens	4-13
12576084-4	2003	The deamidase activity was inhibited by Ebelactone B and the serine protease inhibitor, phenylmethanesulfonyl fluoride (PMSF), while the degradation of the synthetic stereoisomer, Asn-Trp-Phe-NH(2) (N(l)WF-NH(2)), was sensitive to the divalent cation-chelating agent, o-phenanthroline, and aminopeptidase inhibitors, amastatin and bestatin.	amastatin	317-326	cathepsin A	Homo sapiens	4-13
12576084-4	2003	The deamidase activity was inhibited by Ebelactone B and the serine protease inhibitor, phenylmethanesulfonyl fluoride (PMSF), while the degradation of the synthetic stereoisomer, Asn-Trp-Phe-NH(2) (N(l)WF-NH(2)), was sensitive to the divalent cation-chelating agent, o-phenanthroline, and aminopeptidase inhibitors, amastatin and bestatin.	ubenimex	331-339	cathepsin A	Homo sapiens	4-13
12409508-5	2002	An increased GSL biosynthesis was also observed by means of radiolabeled lipid precursors including sphingosine and lactosylceramide.	Sphingosine	100-111	cathepsin A	Homo sapiens	13-16
14737963-0	2003	Effects of ebelactone B on cathepsin A activity in intact platelets and on platelet activation.	ebelactone B	11-23	cathepsin A	Homo sapiens	27-38
14737963-1	2003	PURPOSE: Previous in vitro studies have demonstrated that a potent antihypertensive agent ebelactone B inhibits cathepsin A/deamidase activity.	ebelactone B	90-102	cathepsin A	Homo sapiens	112-133
14737963-4	2003	Cathepsin A activity in platelets was assayed colorimetrically using Cbz-Phe-Ala at pH 5.5.	cbz-phe-ala	69-80	cathepsin A	Homo sapiens	0-11
14737963-6	2003	RESULTS: Pre-treatment of platelets for up to 60 minutes with 10 mumol/l ebelactone B, that effectively inhibits cathepsin A activity in platelet lysate, did not affect this activity in intact platelets.	ebelactone B	73-85	cathepsin A	Homo sapiens	113-124
12409508-5	2002	An increased GSL biosynthesis was also observed by means of radiolabeled lipid precursors including sphingosine and lactosylceramide.	CDw17 antigen	116-132	cathepsin A	Homo sapiens	13-16
12409508-8	2002	Since an inverse relationship between GP expression and GSL content does exist, we assume that increased glycosphingolipid biosynthesis is secondary to protein hypoglycosylation.	Glycosphingolipids	105-122	cathepsin A	Homo sapiens	56-59
12364551-9	2002	The unique biological and physico-chemical properties of adaGb(3) suggest that this analog may be a potent soluble mimic of Gb(3), providing a novel concept for developing GSL-derived viral fusion inhibitors.	adagb(3)	57-65	cathepsin A	Homo sapiens	172-175
10749558-4	2000	The carboxypeptidase activity of cathepsin A was assayed at pH 5.0 with its specific substrate Cbz-Phe-Ala.	cbz-phe-ala	95-106	cathepsin A	Homo sapiens	33-44
11814851-2	2002	Conjugates of cellobiosyl ceramide and melibiosyl ceramide were synthetically prepared as water-soluble GSL analogues.	cellobiosyl ceramide	14-34	cathepsin A	Homo sapiens	104-107
11814851-2	2002	Conjugates of cellobiosyl ceramide and melibiosyl ceramide were synthetically prepared as water-soluble GSL analogues.	melibiosylceramide	39-58	cathepsin A	Homo sapiens	104-107
11814851-2	2002	Conjugates of cellobiosyl ceramide and melibiosyl ceramide were synthetically prepared as water-soluble GSL analogues.	Water	90-95	cathepsin A	Homo sapiens	104-107
11243730-8	2001	To further examine the possible mechanism of GSL accumulation in MPS IIID brains, we employed a cell culture model using suramin-treated neuronal cultures of differentiated P19 cells.	Suramin	121-128	cathepsin A	Homo sapiens	45-48
11243730-10	2001	Metabolic pulse-chase labeling study revealed that the GSL accumulation in suramin-treated cells may be attributed to both disturbed biosynthesis and significantly slower degradation of GSLs.	Suramin	75-82	cathepsin A	Homo sapiens	55-58
11243730-10	2001	Metabolic pulse-chase labeling study revealed that the GSL accumulation in suramin-treated cells may be attributed to both disturbed biosynthesis and significantly slower degradation of GSLs.	Glycosphingolipids	186-190	cathepsin A	Homo sapiens	55-58
11201785-2	2000	GSL clustering in such microdomains causes adhesion to complementary GSLs on the surface of counterpart cells or presented on plastic surfaces, through carbohydrate-to-carbohydrate interaction.	Glycosphingolipids	69-73	cathepsin A	Homo sapiens	0-3
11201785-2	2000	GSL clustering in such microdomains causes adhesion to complementary GSLs on the surface of counterpart cells or presented on plastic surfaces, through carbohydrate-to-carbohydrate interaction.	Carbohydrates	152-164	cathepsin A	Homo sapiens	0-3
11201785-2	2000	GSL clustering in such microdomains causes adhesion to complementary GSLs on the surface of counterpart cells or presented on plastic surfaces, through carbohydrate-to-carbohydrate interaction.	Carbohydrates	168-180	cathepsin A	Homo sapiens	0-3
10201585-11	1999	CONCLUSION: Phaco-GSL and PCIOL implantation is effective in reducing PAS and IOP and improving visual acuity in eyes with persistent chronic ACG when performed within 6 months after treatment for acute ACG.	Aminosalicylic Acid	70-73	cathepsin A	Homo sapiens	18-21
10451385-3	1999	Oxidation of peracetylated GSL precursors with stoichiometric proportions of KMnO4 and an excess of NaIO4, in a neutral aqueous tert-butanol solvent system, gave nearly quantitative yields of the glycosyl ceramide acid, 2-hydroxy-3-(N-acyl)-4-(O-glycosyl)oxybutyric acid [Mylvaganam, M., and Lingwood, C. A.	Potassium Permanganate	77-82	cathepsin A	Homo sapiens	27-30
10451385-3	1999	Oxidation of peracetylated GSL precursors with stoichiometric proportions of KMnO4 and an excess of NaIO4, in a neutral aqueous tert-butanol solvent system, gave nearly quantitative yields of the glycosyl ceramide acid, 2-hydroxy-3-(N-acyl)-4-(O-glycosyl)oxybutyric acid [Mylvaganam, M., and Lingwood, C. A.	metaperiodate	100-105	cathepsin A	Homo sapiens	27-30
10451385-3	1999	Oxidation of peracetylated GSL precursors with stoichiometric proportions of KMnO4 and an excess of NaIO4, in a neutral aqueous tert-butanol solvent system, gave nearly quantitative yields of the glycosyl ceramide acid, 2-hydroxy-3-(N-acyl)-4-(O-glycosyl)oxybutyric acid [Mylvaganam, M., and Lingwood, C. A.	tert-Butyl Alcohol	128-140	cathepsin A	Homo sapiens	27-30
10451385-3	1999	Oxidation of peracetylated GSL precursors with stoichiometric proportions of KMnO4 and an excess of NaIO4, in a neutral aqueous tert-butanol solvent system, gave nearly quantitative yields of the glycosyl ceramide acid, 2-hydroxy-3-(N-acyl)-4-(O-glycosyl)oxybutyric acid [Mylvaganam, M., and Lingwood, C. A.	glycosyl ceramide acid	196-218	cathepsin A	Homo sapiens	27-30
10451385-3	1999	Oxidation of peracetylated GSL precursors with stoichiometric proportions of KMnO4 and an excess of NaIO4, in a neutral aqueous tert-butanol solvent system, gave nearly quantitative yields of the glycosyl ceramide acid, 2-hydroxy-3-(N-acyl)-4-(O-glycosyl)oxybutyric acid [Mylvaganam, M., and Lingwood, C. A.	2-hydroxy-3-(n-acyl)-4-(o-glycosyl)oxybutyric acid	220-270	cathepsin A	Homo sapiens	27-30
10451385-3	1999	Oxidation of peracetylated GSL precursors with stoichiometric proportions of KMnO4 and an excess of NaIO4, in a neutral aqueous tert-butanol solvent system, gave nearly quantitative yields of the glycosyl ceramide acid, 2-hydroxy-3-(N-acyl)-4-(O-glycosyl)oxybutyric acid [Mylvaganam, M., and Lingwood, C. A.	mylvaganam	272-282	cathepsin A	Homo sapiens	27-30
10451385-14	1999	These CID patterns were then used in the identification of serine and ceramide acids synthesized from natural GSL samples.	Serine	59-65	cathepsin A	Homo sapiens	110-113
10451385-14	1999	These CID patterns were then used in the identification of serine and ceramide acids synthesized from natural GSL samples.	ceramide acids	70-84	cathepsin A	Homo sapiens	110-113
10430909-6	1999	The results demonstrate that the synthesis of GSL structures is essential for embryonic development and for the differentiation of some tissues and support the concept that GSLs are involved in crucial cell interactions mediating these processes.	Glycosphingolipids	173-177	cathepsin A	Homo sapiens	46-49
10944848-4	2000	The results show that the K453E mutation is located at the dimer interface of the PPCA and reduces the hydrogen bond formation in the dimer.	Hydrogen	103-111	cathepsin A	Homo sapiens	82-86
10542213-5	1999	Deamidase and transglutaminase activities were blocked in the mutant proteins Cys(1292) --> Ala, His(1307) --> Ala, and Lys(1310) --> Ala of DeltaDNT.	Cysteine	78-81	cathepsin A	Homo sapiens	0-9
10542213-5	1999	Deamidase and transglutaminase activities were blocked in the mutant proteins Cys(1292) --> Ala, His(1307) --> Ala, and Lys(1310) --> Ala of DeltaDNT.	Alanine	95-98	cathepsin A	Homo sapiens	0-9
10542213-5	1999	Deamidase and transglutaminase activities were blocked in the mutant proteins Cys(1292) --> Ala, His(1307) --> Ala, and Lys(1310) --> Ala of DeltaDNT.	Histidine	100-103	cathepsin A	Homo sapiens	0-9
10542213-5	1999	Deamidase and transglutaminase activities were blocked in the mutant proteins Cys(1292) --> Ala, His(1307) --> Ala, and Lys(1310) --> Ala of DeltaDNT.	Alanine	117-120	cathepsin A	Homo sapiens	0-9
10542213-5	1999	Deamidase and transglutaminase activities were blocked in the mutant proteins Cys(1292) --> Ala, His(1307) --> Ala, and Lys(1310) --> Ala of DeltaDNT.	Lysine	126-129	cathepsin A	Homo sapiens	0-9
10542213-5	1999	Deamidase and transglutaminase activities were blocked in the mutant proteins Cys(1292) --> Ala, His(1307) --> Ala, and Lys(1310) --> Ala of DeltaDNT.	Alanine	117-120	cathepsin A	Homo sapiens	0-9
10225457-3	1999	We have shown previously that LMP1 is highly concentrated in a cell fraction called glycosphingolipid-rich membrane complexes (GSL complexes).	Glycosphingolipids	84-101	cathepsin A	Homo sapiens	127-130
9529158-2	1998	We have previously reported that lactosylceramide (LacCer), a ubiquitous GSL, stimulates NADPH oxidase-dependent superoxide generation by aortic smooth muscle cells and their consequent proliferation.	CDw17 antigen	33-49	cathepsin A	Homo sapiens	73-76
9890884-3	1999	We proposed that these regions represent putative phosphotransferase-binding sites and tested synthetic peptides, derived from these regions on the basis of surface accessibility, for their ability to inhibit in vitro phosphorylation of purified cathepsins A, B, and D. Our results indicate that cathepsin A and cathepsin D have one closely related phosphotransferase recognition site represented by a structurally and topologically conserved beta-hairpin loop, similar to that previously identified in lysosomal beta-glucuronidase.	Peptides	104-112	cathepsin A	Homo sapiens	296-307
10218108-5	1999	The remainder of the review encompasses the metabolic steps devoted to (a) the salvaging of various niacin derivatives, including the roles played by NAD+ and NADH pyrophosphatases, nicotinamide deamidase, and NMN deamidase, and (b) utilization of niacins by nicotinate phosphoribosyltransferase and nicotinamide phosphoribosyltransferase.	Niacin	100-106	cathepsin A	Homo sapiens	214-223
10526436-3	1999	Cathepsin A activity was determined by the ninhydrin method with synthetic substrate (N-Cbz-Phe-Ala) at its optimum pH 5.0.	Ninhydrin	43-52	cathepsin A	Homo sapiens	0-11
10526436-3	1999	Cathepsin A activity was determined by the ninhydrin method with synthetic substrate (N-Cbz-Phe-Ala) at its optimum pH 5.0.	n-cbz-phe-ala	86-99	cathepsin A	Homo sapiens	0-11
10526437-3	1999	Cathepsin A activity was determined by the ninhydrin method with synthetic substrate (N-Cbz-Phe-Ala) at its optimum pH 5.0.	Ninhydrin	43-52	cathepsin A	Homo sapiens	0-11
10526437-3	1999	Cathepsin A activity was determined by the ninhydrin method with synthetic substrate (N-Cbz-Phe-Ala) at its optimum pH 5.0.	n-cbz-phe-ala	86-99	cathepsin A	Homo sapiens	0-11
9826718-1	1998	Previously, we showed that the addition of human erythrocyte glycosphingolipids (GSLs) to nonhuman CD4(+) or GSL-depleted human CD4(+) cells rendered those cells susceptible to HIV-1 envelope glycoprotein-mediated cell fusion.	Glycosphingolipids	61-79	cathepsin A	Homo sapiens	81-84
9826718-2	1998	Individual components in the GSL mixture were isolated by fractionation on a silica-gel column and incorporated into the membranes of CD4(+) cells.	Silicon Dioxide	77-83	cathepsin A	Homo sapiens	29-32
9529158-2	1998	We have previously reported that lactosylceramide (LacCer), a ubiquitous GSL, stimulates NADPH oxidase-dependent superoxide generation by aortic smooth muscle cells and their consequent proliferation.	CDw17 antigen	51-57	cathepsin A	Homo sapiens	73-76
9529158-2	1998	We have previously reported that lactosylceramide (LacCer), a ubiquitous GSL, stimulates NADPH oxidase-dependent superoxide generation by aortic smooth muscle cells and their consequent proliferation.	Superoxides	113-123	cathepsin A	Homo sapiens	73-76
7583534-5	1995	GSL levels in plaques were highest: GlcCer was 18- and 8-fold, LacCer was 8- and 7-fold, and GM3 was 2.5- and 12-fold higher than in musculoelastic and elastic-hyperplastic intimal layers of normal regions, respectively.	gm3	93-96	cathepsin A	Homo sapiens	0-3
16793668-4	1997	Human platelet cathepsin A-type enzyme hydrolyzed at the highest rate Cbz-Phe-Ala, Cbz-Phe-Met and Cbz-Phe-Leu, did not require sulfhydryl activator and was inhibited by serine protease inhibitors (DFP, DCI) and inhibitors that react with the SH group (mersalyl acid, PCMS, PCMB, HgCl2).	cbz-phe-ala	70-81	cathepsin A	Homo sapiens	15-26
16793668-4	1997	Human platelet cathepsin A-type enzyme hydrolyzed at the highest rate Cbz-Phe-Ala, Cbz-Phe-Met and Cbz-Phe-Leu, did not require sulfhydryl activator and was inhibited by serine protease inhibitors (DFP, DCI) and inhibitors that react with the SH group (mersalyl acid, PCMS, PCMB, HgCl2).	carbobenzoxyphenylalanylmethionine	83-94	cathepsin A	Homo sapiens	15-26
16793668-4	1997	Human platelet cathepsin A-type enzyme hydrolyzed at the highest rate Cbz-Phe-Ala, Cbz-Phe-Met and Cbz-Phe-Leu, did not require sulfhydryl activator and was inhibited by serine protease inhibitors (DFP, DCI) and inhibitors that react with the SH group (mersalyl acid, PCMS, PCMB, HgCl2).	cbz-phe-leu	99-110	cathepsin A	Homo sapiens	15-26
16793668-4	1997	Human platelet cathepsin A-type enzyme hydrolyzed at the highest rate Cbz-Phe-Ala, Cbz-Phe-Met and Cbz-Phe-Leu, did not require sulfhydryl activator and was inhibited by serine protease inhibitors (DFP, DCI) and inhibitors that react with the SH group (mersalyl acid, PCMS, PCMB, HgCl2).	Isoflurophate	198-201	cathepsin A	Homo sapiens	15-26
16793668-4	1997	Human platelet cathepsin A-type enzyme hydrolyzed at the highest rate Cbz-Phe-Ala, Cbz-Phe-Met and Cbz-Phe-Leu, did not require sulfhydryl activator and was inhibited by serine protease inhibitors (DFP, DCI) and inhibitors that react with the SH group (mersalyl acid, PCMS, PCMB, HgCl2).	Mersalyl	253-266	cathepsin A	Homo sapiens	15-26
16793668-4	1997	Human platelet cathepsin A-type enzyme hydrolyzed at the highest rate Cbz-Phe-Ala, Cbz-Phe-Met and Cbz-Phe-Leu, did not require sulfhydryl activator and was inhibited by serine protease inhibitors (DFP, DCI) and inhibitors that react with the SH group (mersalyl acid, PCMS, PCMB, HgCl2).	acetaminophen sulfate ester	268-272	cathepsin A	Homo sapiens	15-26
16793668-4	1997	Human platelet cathepsin A-type enzyme hydrolyzed at the highest rate Cbz-Phe-Ala, Cbz-Phe-Met and Cbz-Phe-Leu, did not require sulfhydryl activator and was inhibited by serine protease inhibitors (DFP, DCI) and inhibitors that react with the SH group (mersalyl acid, PCMS, PCMB, HgCl2).	p-Chloromercuribenzoic Acid	274-278	cathepsin A	Homo sapiens	15-26
16793668-4	1997	Human platelet cathepsin A-type enzyme hydrolyzed at the highest rate Cbz-Phe-Ala, Cbz-Phe-Met and Cbz-Phe-Leu, did not require sulfhydryl activator and was inhibited by serine protease inhibitors (DFP, DCI) and inhibitors that react with the SH group (mersalyl acid, PCMS, PCMB, HgCl2).	Mercuric Chloride	280-285	cathepsin A	Homo sapiens	15-26
8910459-8	1996	Gel filtration analysis of fibroblast extracts of patients deficient in either beta-galactosidase (beta-galactosidosis) or cathepsin A (galactosialidosis), which accumulate KS, demonstrates that the 1.27-MDa complex is disrupted and that GALNS is present only in free homodimeric form.	Keratan Sulfate	173-175	cathepsin A	Homo sapiens	123-134
15157485-4	1996	Some activator proteins bind to GSLs and form water-soluble complexes, which lift out of the membrane and give the water-soluble hydrolysing enzymes access to the regions of the GSL that would otherwise be obscured by the membrane.	Water	46-51	cathepsin A	Homo sapiens	32-35
15157485-4	1996	Some activator proteins bind to GSLs and form water-soluble complexes, which lift out of the membrane and give the water-soluble hydrolysing enzymes access to the regions of the GSL that would otherwise be obscured by the membrane.	Water	115-120	cathepsin A	Homo sapiens	32-35
9553770-8	1998	Whereas deamidase cleaves a variety of peptides with C-terminal or penultimate hydrophobic residues (e.g. substance P, angiotensin I, bradykinin, endothelin, fMet-Leu-Phe).	Leucine	163-166	cathepsin A	Homo sapiens	8-17
9553770-8	1998	Whereas deamidase cleaves a variety of peptides with C-terminal or penultimate hydrophobic residues (e.g. substance P, angiotensin I, bradykinin, endothelin, fMet-Leu-Phe).	Phenylalanine	167-170	cathepsin A	Homo sapiens	8-17
9435242-1	1998	Human protective protein/cathepsin A (PPCA), a serine carboxypeptidase, forms a multienzyme complex with beta-galactosidase and neuraminidase and is required for the intralysosomal activity and stability of these two glycosidases.	Serine	47-53	cathepsin A	Homo sapiens	6-36
9435242-1	1998	Human protective protein/cathepsin A (PPCA), a serine carboxypeptidase, forms a multienzyme complex with beta-galactosidase and neuraminidase and is required for the intralysosomal activity and stability of these two glycosidases.	Serine	47-53	cathepsin A	Homo sapiens	38-42
9821867-7	1998	However, when GSL carbohydrates were calculated as percentage of total carbohydrates, GSLs in leukemic leukocytes were elevated in half of the AML patients but depressed in the other half.	Glycosphingolipids	86-90	cathepsin A	Homo sapiens	14-17
9379666-4	1997	Cathepsin A activity was determined by the ninhydrin method with synthetic substrate (N-Cbz-Phe-Ala) at its optimum pH 5.0.	Ninhydrin	43-52	cathepsin A	Homo sapiens	0-11
9379666-4	1997	Cathepsin A activity was determined by the ninhydrin method with synthetic substrate (N-Cbz-Phe-Ala) at its optimum pH 5.0.	n-cbz-phe-ala	86-99	cathepsin A	Homo sapiens	0-11
8660611-4	1996	GSL containing silica gel was scraped off and extracted with chloroform:methanol:water (30:60:8, by vol).	Silica Gel	15-25	cathepsin A	Homo sapiens	0-3
8660611-4	1996	GSL containing silica gel was scraped off and extracted with chloroform:methanol:water (30:60:8, by vol).	Chloroform	61-71	cathepsin A	Homo sapiens	0-3
8660611-4	1996	GSL containing silica gel was scraped off and extracted with chloroform:methanol:water (30:60:8, by vol).	Methanol	72-80	cathepsin A	Homo sapiens	0-3
8660611-4	1996	GSL containing silica gel was scraped off and extracted with chloroform:methanol:water (30:60:8, by vol).	Water	81-86	cathepsin A	Homo sapiens	0-3
8660611-6	1996	Finally, a stepwise chloroform:methanol gradient chromatography on a small silica gel K60 column was employed to remove non-GSL impurities.	Chloroform	20-30	cathepsin A	Homo sapiens	124-127
8660611-6	1996	Finally, a stepwise chloroform:methanol gradient chromatography on a small silica gel K60 column was employed to remove non-GSL impurities.	Methanol	31-39	cathepsin A	Homo sapiens	124-127
8660611-8	1996	The method was proved with reference GSL mixtures containing glucosyl-, galactosyl-, lactosyl-, globotriaosyl-, and neolactotetraosylceramides, each substituted with C24- and C16-fatty acids, resulting in isolation of individual GSL fractions.	glucosyl-, galactosyl-, lactosyl-, globotriaosyl-, and neolactotetraosylceramides	61-142	cathepsin A	Homo sapiens	229-232
8660611-8	1996	The method was proved with reference GSL mixtures containing glucosyl-, galactosyl-, lactosyl-, globotriaosyl-, and neolactotetraosylceramides, each substituted with C24- and C16-fatty acids, resulting in isolation of individual GSL fractions.	c24- and c16-fatty acids	166-190	cathepsin A	Homo sapiens	37-40
8660611-8	1996	The method was proved with reference GSL mixtures containing glucosyl-, galactosyl-, lactosyl-, globotriaosyl-, and neolactotetraosylceramides, each substituted with C24- and C16-fatty acids, resulting in isolation of individual GSL fractions.	c24- and c16-fatty acids	166-190	cathepsin A	Homo sapiens	229-232
9104505-2	1996	Cathepsin A exhibited a pH optimum at 5.0 and showed the highest specificity towards N-Cbz-Phe-Ala as a substrate.	n-cbz-phe-ala	85-98	cathepsin A	Homo sapiens	0-11
9112639-3	1996	Indomethacin, phenacetin and aminophenazone were the most potent inhibitors of cathepsin A.	Indomethacin	0-12	cathepsin A	Homo sapiens	79-90
9112639-3	1996	Indomethacin, phenacetin and aminophenazone were the most potent inhibitors of cathepsin A.	Phenacetin	14-24	cathepsin A	Homo sapiens	79-90
9112639-3	1996	Indomethacin, phenacetin and aminophenazone were the most potent inhibitors of cathepsin A.	Aminopyrine	29-43	cathepsin A	Homo sapiens	79-90
9112639-4	1996	Acetylsalicylic acid added to platelet lysate inhibited cathepsin A in the same extent as salicylate.	Aspirin	0-20	cathepsin A	Homo sapiens	56-67
7503422-1	1995	We describe a method to determine the substrate specificity of human lysosomal carboxypeptidase, cathepsin A/protective protein, using furylacryloyl (FA)-Phe-X dipeptides as substrates.	furylacryloyl	135-148	cathepsin A	Homo sapiens	97-108
7503422-1	1995	We describe a method to determine the substrate specificity of human lysosomal carboxypeptidase, cathepsin A/protective protein, using furylacryloyl (FA)-Phe-X dipeptides as substrates.	phe-x	154-159	cathepsin A	Homo sapiens	97-108
7503422-1	1995	We describe a method to determine the substrate specificity of human lysosomal carboxypeptidase, cathepsin A/protective protein, using furylacryloyl (FA)-Phe-X dipeptides as substrates.	Dipeptides	160-170	cathepsin A	Homo sapiens	97-108
7503422-3	1995	The results obtained with cathepsin A purified from human placenta demonstrate that the enzyme has the highest affinity for substrates with large hydrophobic (Phe, Leu) or positively charged (Arg) amino acid residues in P1" position.	Phenylalanine	159-162	cathepsin A	Homo sapiens	26-37
7503422-3	1995	The results obtained with cathepsin A purified from human placenta demonstrate that the enzyme has the highest affinity for substrates with large hydrophobic (Phe, Leu) or positively charged (Arg) amino acid residues in P1" position.	Leucine	164-167	cathepsin A	Homo sapiens	26-37
7503422-3	1995	The results obtained with cathepsin A purified from human placenta demonstrate that the enzyme has the highest affinity for substrates with large hydrophobic (Phe, Leu) or positively charged (Arg) amino acid residues in P1" position.	Arginine	192-195	cathepsin A	Homo sapiens	26-37
7626287-6	1995	Deamidase in human alveolar macrophages, obtained by bronchoalveolar lavage from 23 patients, cleaved dansyl-Phe-Leu-Arg at a rate of 2.26 mumol/h/mg protein and hydrolyzed the chemotactic peptide N-f-Met-Leu-Phe even faster, at a rate of 53.1 mumol/h/mg protein, the highest activity for this enzyme with any of the cells we tested.	dansyl-phe-leu-arg	102-120	cathepsin A	Homo sapiens	0-9
7626287-6	1995	Deamidase in human alveolar macrophages, obtained by bronchoalveolar lavage from 23 patients, cleaved dansyl-Phe-Leu-Arg at a rate of 2.26 mumol/h/mg protein and hydrolyzed the chemotactic peptide N-f-Met-Leu-Phe even faster, at a rate of 53.1 mumol/h/mg protein, the highest activity for this enzyme with any of the cells we tested.	Peptides	189-196	cathepsin A	Homo sapiens	0-9
7626287-6	1995	Deamidase in human alveolar macrophages, obtained by bronchoalveolar lavage from 23 patients, cleaved dansyl-Phe-Leu-Arg at a rate of 2.26 mumol/h/mg protein and hydrolyzed the chemotactic peptide N-f-Met-Leu-Phe even faster, at a rate of 53.1 mumol/h/mg protein, the highest activity for this enzyme with any of the cells we tested.	n-f-met-leu-phe	197-212	cathepsin A	Homo sapiens	0-9
8528992-0	1995	The activity of cathepsin A and cathepsin D in the serum of persons acutely intoxicated with ethanol and chronic alcoholics.	Ethanol	93-100	cathepsin A	Homo sapiens	16-27
7756331-6	1995	In general, order along the GSL chain was slightly higher than anticipated for equivalent chain segments in phospholipids.	Phospholipids	108-121	cathepsin A	Homo sapiens	28-31
7756331-13	1995	These results suggest that fluid membrane area requirements for GSLs with saturated fatty acids are not strongly influenced by the nature of that fatty acid when the GSL is a minor component.	Fatty Acids	74-95	cathepsin A	Homo sapiens	64-67
7756331-14	1995	Order parameter profiles for the very long chain GSL deviated to higher order below this point, and formed a second "plateau" of reduced negative slope toward the methyl terminus: this is characteristic of profiles for very long chain GSLs.	Glycosphingolipids	235-239	cathepsin A	Homo sapiens	49-52
7711240-11	1995	SCD values at C16 and C17 were about 15% and 28% higher, respectively, for the long chain GSL than for its short chain analogue inSOPC/cholesterol (compared to 21 and 31%, respectively, in membranes without cholesterol).	Cholesterol	135-146	cathepsin A	Homo sapiens	90-93
8528992-2	1995	Persons acutely intoxicated with ethanol had the unchanged activity of cathepsin A and cathepsin D while it increased in the chronic alcoholic serum.	Ethanol	33-40	cathepsin A	Homo sapiens	71-82
8094595-3	1993	New dinucleotide repeat polymorphisms associated with the D20S17, PPGB, and ADA loci have been identified and mapped.	Dinucleoside Phosphates	4-16	cathepsin A	Homo sapiens	66-70
8053688-7	1994	Such a dual function of cathepsin A is also confirmed by our finding that it is the only carboxypeptidase of placenta extract able to catalyze the hydrolysis of both carbobenzoxy (CBZ)-Glu-Tyr and CBZ-Phe-Leu dipeptide substrates.	carbobenzoxy (cbz)-glu-tyr	166-192	cathepsin A	Homo sapiens	24-35
8053688-7	1994	Such a dual function of cathepsin A is also confirmed by our finding that it is the only carboxypeptidase of placenta extract able to catalyze the hydrolysis of both carbobenzoxy (CBZ)-Glu-Tyr and CBZ-Phe-Leu dipeptide substrates.	cbz-phe-leu dipeptide	197-218	cathepsin A	Homo sapiens	24-35
8505102-4	1993	The final supernatant of the homogenized cells (S3) cleaved the deamidase substrate dansyl-Phe-Leu-Arg at a rate of 1.3 nmol/min per 10(6) cells at pH 5.5 at 37 degrees C. Endothelin-1 was completely inactivated by the S3 fraction as determined on rat thoracic aorta strips.	dansyl-phe-leu-arg	84-102	cathepsin A	Homo sapiens	64-73
8481397-6	1993	In such cells, LDL exerted a concentration-dependent stimulation of [3H]glucose and [3H]serine incorporation into GSL.	Tritium	85-87	cathepsin A	Homo sapiens	114-117
8481397-6	1993	In such cells, LDL exerted a concentration-dependent stimulation of [3H]glucose and [3H]serine incorporation into GSL.	Serine	88-94	cathepsin A	Homo sapiens	114-117
1737744-1	1992	Deamidase cleaves ester and peptide bonds in various substrates and deamidates protected COOH-terminal amino acids.	Esters	18-23	cathepsin A	Homo sapiens	0-9
1306306-1	1992	Molecular modeling of glycosphingolipids (GSLs), and their organization in membranes, suggest that GSL "patches" provide binding sites for interaction with ligands and adjacent cells, and that GSLs or their catabolites modulate transmembrane signaling.	Glycosphingolipids	22-40	cathepsin A	Homo sapiens	42-45
1306306-1	1992	Molecular modeling of glycosphingolipids (GSLs), and their organization in membranes, suggest that GSL "patches" provide binding sites for interaction with ligands and adjacent cells, and that GSLs or their catabolites modulate transmembrane signaling.	Glycosphingolipids	193-197	cathepsin A	Homo sapiens	42-45
1516732-2	1992	A correct assay for cathepsin A was developed by adding 0.1 M NaNO3 as an enzyme stabilizer to the assay system.	sodium nitrate	62-67	cathepsin A	Homo sapiens	20-31
1516732-4	1992	Cathepsin A was purified homogeneously from porcine spleen by DE 52 column, Sephadex G-150 column and Try-Phe-CH-Sepharose column chromatography.	sephadex	76-84	cathepsin A	Homo sapiens	0-11
1516732-4	1992	Cathepsin A was purified homogeneously from porcine spleen by DE 52 column, Sephadex G-150 column and Try-Phe-CH-Sepharose column chromatography.	Phenylalanine	106-109	cathepsin A	Homo sapiens	0-11
1516732-4	1992	Cathepsin A was purified homogeneously from porcine spleen by DE 52 column, Sephadex G-150 column and Try-Phe-CH-Sepharose column chromatography.	Sepharose	113-122	cathepsin A	Homo sapiens	0-11
1516732-8	1992	Chaotropic agents exerted stabilizing effects on the purified cathepsin A activity at pH 5.0, with sodium nitrate being the most effective among the agents tested.	sodium nitrate	99-113	cathepsin A	Homo sapiens	62-73
1516732-10	1992	Cathepsin A was inactivated rapidly and irreversibly by thiols.	Sulfhydryl Compounds	56-62	cathepsin A	Homo sapiens	0-11
1737744-7	1992	The reaction was inhibited by diisopropyl fluorophosphate, benzyloxycarbonyl-Gly-Leu-Phe-CH2Cl, and p-chloromercuribenzenesulfonate, which inhibit the purified deamidase, but not by inhibitors of some other peptidases.	Isoflurophate	30-57	cathepsin A	Homo sapiens	160-169
1737744-7	1992	The reaction was inhibited by diisopropyl fluorophosphate, benzyloxycarbonyl-Gly-Leu-Phe-CH2Cl, and p-chloromercuribenzenesulfonate, which inhibit the purified deamidase, but not by inhibitors of some other peptidases.	N-benzyloxycarbonylglycyl-leucyl-phenylalanine chloromethyl ketone	59-94	cathepsin A	Homo sapiens	160-169
1737744-7	1992	The reaction was inhibited by diisopropyl fluorophosphate, benzyloxycarbonyl-Gly-Leu-Phe-CH2Cl, and p-chloromercuribenzenesulfonate, which inhibit the purified deamidase, but not by inhibitors of some other peptidases.	4-Chloromercuribenzenesulfonate	100-131	cathepsin A	Homo sapiens	160-169
1737744-9	1992	Thus, smooth muscles, platelets, and many other tissues which contain the deamidase can inactivate endothelin by cleaving the COOH-terminal tryptophan.	Carbonic Acid	126-130	cathepsin A	Homo sapiens	74-83
1737744-9	1992	Thus, smooth muscles, platelets, and many other tissues which contain the deamidase can inactivate endothelin by cleaving the COOH-terminal tryptophan.	Tryptophan	140-150	cathepsin A	Homo sapiens	74-83
1739742-3	1992	The GSL of the dipteran insects, L. caesar and C. vicina, consist of a series of homologous compounds of increasing sugar chain length.	Sugars	116-121	cathepsin A	Homo sapiens	4-7
1739742-4	1992	The carbohydrate moieties of these arthropod GSL are all derived from one unique neutral sugar core sequence, the arthro-series.	Carbohydrates	4-16	cathepsin A	Homo sapiens	45-48
1739742-4	1992	The carbohydrate moieties of these arthropod GSL are all derived from one unique neutral sugar core sequence, the arthro-series.	Sugars	89-94	cathepsin A	Homo sapiens	45-48
1739742-7	1992	A large repertoire of structural variations of the arthro-series GSL is created by two types of derivatisations of the neutral carbohydrate core: addition of a zwitterionic 2-aminoethylphosphate group in phosphodiester linkage to the 6-position of the III-N-acetylglucosamine of the arthrotriaosylceramide core and/or substitution of a terminal galactose in 3-position by a glucuronic acid residue.	D-GLUCOSAMINE SULFATE	51-57	cathepsin A	Homo sapiens	65-68
1739742-7	1992	A large repertoire of structural variations of the arthro-series GSL is created by two types of derivatisations of the neutral carbohydrate core: addition of a zwitterionic 2-aminoethylphosphate group in phosphodiester linkage to the 6-position of the III-N-acetylglucosamine of the arthrotriaosylceramide core and/or substitution of a terminal galactose in 3-position by a glucuronic acid residue.	Carbohydrates	127-139	cathepsin A	Homo sapiens	65-68
1739742-7	1992	A large repertoire of structural variations of the arthro-series GSL is created by two types of derivatisations of the neutral carbohydrate core: addition of a zwitterionic 2-aminoethylphosphate group in phosphodiester linkage to the 6-position of the III-N-acetylglucosamine of the arthrotriaosylceramide core and/or substitution of a terminal galactose in 3-position by a glucuronic acid residue.	2-aminoethyl phosphate	173-194	cathepsin A	Homo sapiens	65-68
1739742-7	1992	A large repertoire of structural variations of the arthro-series GSL is created by two types of derivatisations of the neutral carbohydrate core: addition of a zwitterionic 2-aminoethylphosphate group in phosphodiester linkage to the 6-position of the III-N-acetylglucosamine of the arthrotriaosylceramide core and/or substitution of a terminal galactose in 3-position by a glucuronic acid residue.	iii-n-acetylglucosamine	252-275	cathepsin A	Homo sapiens	65-68
1739742-7	1992	A large repertoire of structural variations of the arthro-series GSL is created by two types of derivatisations of the neutral carbohydrate core: addition of a zwitterionic 2-aminoethylphosphate group in phosphodiester linkage to the 6-position of the III-N-acetylglucosamine of the arthrotriaosylceramide core and/or substitution of a terminal galactose in 3-position by a glucuronic acid residue.	arthrotriaosylceramide	283-305	cathepsin A	Homo sapiens	65-68
1739742-7	1992	A large repertoire of structural variations of the arthro-series GSL is created by two types of derivatisations of the neutral carbohydrate core: addition of a zwitterionic 2-aminoethylphosphate group in phosphodiester linkage to the 6-position of the III-N-acetylglucosamine of the arthrotriaosylceramide core and/or substitution of a terminal galactose in 3-position by a glucuronic acid residue.	Galactose	345-354	cathepsin A	Homo sapiens	65-68
1739742-7	1992	A large repertoire of structural variations of the arthro-series GSL is created by two types of derivatisations of the neutral carbohydrate core: addition of a zwitterionic 2-aminoethylphosphate group in phosphodiester linkage to the 6-position of the III-N-acetylglucosamine of the arthrotriaosylceramide core and/or substitution of a terminal galactose in 3-position by a glucuronic acid residue.	Glucuronic Acid	374-389	cathepsin A	Homo sapiens	65-68
1739742-8	1992	The latter acidic arthro-series GSL were given the name arthrosides.	arthrosides	56-67	cathepsin A	Homo sapiens	32-35
1739742-10	1992	GSL of various larval organs are distinguished by the length of their neutral core carbohydrate chain, as well as, the degree of PEtn- and GlcA-substitutions.	Carbohydrates	83-95	cathepsin A	Homo sapiens	0-3
1739742-10	1992	GSL of various larval organs are distinguished by the length of their neutral core carbohydrate chain, as well as, the degree of PEtn- and GlcA-substitutions.	Pentaerythritol Tetranitrate	129-133	cathepsin A	Homo sapiens	0-3
1739742-10	1992	GSL of various larval organs are distinguished by the length of their neutral core carbohydrate chain, as well as, the degree of PEtn- and GlcA-substitutions.	Glucuronic Acid	139-143	cathepsin A	Homo sapiens	0-3
1694176-12	1990	The deamidase is inhibited by diisopropylfluorophosphate, inhibitors of chymotrypsin-type enzymes, and mercury compounds while other inhibitors of catheptic enzymes, trypsin-like enzymes, and metalloproteases were ineffective.	Isoflurophate	30-56	cathepsin A	Homo sapiens	4-13
1414518-2	1992	In the neutral fraction GSL, a mostly even distribution of mono-, di-, tri-and tetrahexoside was demonstrated.	mono-, di-, tri-and tetrahexoside	59-92	cathepsin A	Homo sapiens	24-27
1694176-12	1990	The deamidase is inhibited by diisopropylfluorophosphate, inhibitors of chymotrypsin-type enzymes, and mercury compounds while other inhibitors of catheptic enzymes, trypsin-like enzymes, and metalloproteases were ineffective.	Mercury	103-110	cathepsin A	Homo sapiens	4-13
1694176-14	1990	After reduction, deamidase dissociates into two chains of Mr = 33,000 and 21,000 as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.	Sodium Dodecyl Sulfate	98-120	cathepsin A	Homo sapiens	17-26
1694176-14	1990	After reduction, deamidase dissociates into two chains of Mr = 33,000 and 21,000 as determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis.	polyacrylamide	121-135	cathepsin A	Homo sapiens	17-26
1688344-1	1990	Cathepsin A activity has been determinal in sera of nonpregnant, pregnant (1st, 2nd and 3rd trimesto), puerperal (first, third and fifth day post partum) and parturient women in second stage (retroplacental blood and blood from umbilical cord) by means of N-Cbz-L-glutamyl-L-tyrosin after incubation with 37 degrees C and pH 5.5.	n-cbz-l-glutamyl-l-tyrosin	256-282	cathepsin A	Homo sapiens	0-11
2110799-4	1990	In particular, surface expression of the major neutral GSL, globoside, decreased three- to fourfold as measured both by galactose oxidase labeling and by binding of the anti-globoside monoclonal antibody 9G7.	Globosides	60-69	cathepsin A	Homo sapiens	55-58
2194428-3	1990	The fine specificity of anti-GSL antibodies should be characterized by analyzing their reactivity with a panel of GSLs with related structures.	Glycosphingolipids	114-118	cathepsin A	Homo sapiens	29-32
34125594-4	2021	Our data collectively demonstrated that carboxylesterase 1 (CES1) and cathepsin A (CatA) are enzymes involved in hydrolyzing RDV to its alanine intermediate Met X, which is further hydrolyzed to the monophosphate form by histidine triad nucleotide-binding protein 1 (HINT1).	remdesivir	125-128	cathepsin A	Homo sapiens	70-81
34402018-10	2022	The D-H causality test supports the GSL findings and further reveals a feedback relationship between PCI and CO2 emissions, ENC causes CO2 emissions, bidirectional causality exists between FD and ENC, PCI causes both ENC and FD, and CO2 emissions cause FD.	Carbon Dioxide	109-112	cathepsin A	Homo sapiens	36-39
34402018-10	2022	The D-H causality test supports the GSL findings and further reveals a feedback relationship between PCI and CO2 emissions, ENC causes CO2 emissions, bidirectional causality exists between FD and ENC, PCI causes both ENC and FD, and CO2 emissions cause FD.	Carbon Dioxide	233-236	cathepsin A	Homo sapiens	36-39
34946974-0	2021	Effects of Genetic Polymorphisms of Cathepsin A on Metabolism of Tenofovir Alafenamide.	Tenofovir	65-74	cathepsin A	Homo sapiens	36-47
34946974-0	2021	Effects of Genetic Polymorphisms of Cathepsin A on Metabolism of Tenofovir Alafenamide.	alafenamide	75-86	cathepsin A	Homo sapiens	36-47
34946974-1	2021	Cathepsin A (CatA) is important as a drug-metabolizing enzyme responsible for the activation of prodrugs, such as the anti-human immunodeficiency virus drug Tenofovir Alafenamide (TAF).	tenofovir alafenamide	157-178	cathepsin A	Homo sapiens	0-11
34946974-1	2021	Cathepsin A (CatA) is important as a drug-metabolizing enzyme responsible for the activation of prodrugs, such as the anti-human immunodeficiency virus drug Tenofovir Alafenamide (TAF).	tenofovir alafenamide	157-178	cathepsin A	Homo sapiens	13-17
34946974-1	2021	Cathepsin A (CatA) is important as a drug-metabolizing enzyme responsible for the activation of prodrugs, such as the anti-human immunodeficiency virus drug Tenofovir Alafenamide (TAF).	tenofovir alafenamide	180-183	cathepsin A	Homo sapiens	0-11
34946974-1	2021	Cathepsin A (CatA) is important as a drug-metabolizing enzyme responsible for the activation of prodrugs, such as the anti-human immunodeficiency virus drug Tenofovir Alafenamide (TAF).	tenofovir alafenamide	180-183	cathepsin A	Homo sapiens	13-17
34946974-5	2021	The polymorphism (85_87CTG>-) in exon 2 was a mutation causing a deletion of leucine, resulting in the change of the leucine 9-repeat (Leu9) to 8-repeat (Leu8) in the signal peptide region of CatA protein.	Leucine	77-84	cathepsin A	Homo sapiens	192-196
34946974-5	2021	The polymorphism (85_87CTG>-) in exon 2 was a mutation causing a deletion of leucine, resulting in the change of the leucine 9-repeat (Leu9) to 8-repeat (Leu8) in the signal peptide region of CatA protein.	Leucine	117-124	cathepsin A	Homo sapiens	192-196
34827655-11	2021	On the other hand, GSLs and other GSL hydrolysis products other than ITCs, such as nitriles, were found in honey produced by the treated bees, potentially increasing the health value of the final product for human consumption.	Nitriles	83-91	cathepsin A	Homo sapiens	34-37
34478702-3	2021	Here, we develop a new strategy for the analysis of lyso-GSL (l-GSL), GSL that retain linkage of the glycan headgroup with the Sph base.	lyso-gsl	52-60	cathepsin A	Homo sapiens	64-67
34478702-3	2021	Here, we develop a new strategy for the analysis of lyso-GSL (l-GSL), GSL that retain linkage of the glycan headgroup with the Sph base.	lyso-gsl	52-60	cathepsin A	Homo sapiens	70-73
34478702-3	2021	Here, we develop a new strategy for the analysis of lyso-GSL (l-GSL), GSL that retain linkage of the glycan headgroup with the Sph base.	Polysaccharides	101-107	cathepsin A	Homo sapiens	70-73
34478702-6	2021	This method was compared analysis of GSL glycans after cleavage by an Endoglycoceramidase (EGCase) enzyme and labeling with a fluorophore (2-anthranilic acid, 2AA).	2-anthranilic acid	139-157	cathepsin A	Homo sapiens	37-40
34370586-2	2021	titled, "Key Metabolic Enzymes in Remdesivir Activation in Lung Cells," validates the canonical McGuigan enzymes (CES1, CTSA, HINT1) involved in remdesivir"s (RDV"s) bioactivation using bioinformatic and biochemical approaches (1).....	remdesivir	34-44	cathepsin A	Homo sapiens	120-124
34370586-2	2021	titled, "Key Metabolic Enzymes in Remdesivir Activation in Lung Cells," validates the canonical McGuigan enzymes (CES1, CTSA, HINT1) involved in remdesivir"s (RDV"s) bioactivation using bioinformatic and biochemical approaches (1).....	remdesivir	145-155	cathepsin A	Homo sapiens	120-124
34125594-4	2021	Our data collectively demonstrated that carboxylesterase 1 (CES1) and cathepsin A (CatA) are enzymes involved in hydrolyzing RDV to its alanine intermediate Met X, which is further hydrolyzed to the monophosphate form by histidine triad nucleotide-binding protein 1 (HINT1).	Alanine	136-143	cathepsin A	Homo sapiens	70-81
34125594-4	2021	Our data collectively demonstrated that carboxylesterase 1 (CES1) and cathepsin A (CatA) are enzymes involved in hydrolyzing RDV to its alanine intermediate Met X, which is further hydrolyzed to the monophosphate form by histidine triad nucleotide-binding protein 1 (HINT1).	Alanine	136-143	cathepsin A	Homo sapiens	83-87
34125594-4	2021	Our data collectively demonstrated that carboxylesterase 1 (CES1) and cathepsin A (CatA) are enzymes involved in hydrolyzing RDV to its alanine intermediate Met X, which is further hydrolyzed to the monophosphate form by histidine triad nucleotide-binding protein 1 (HINT1).	monophosphate	199-212	cathepsin A	Homo sapiens	70-81
34125594-4	2021	Our data collectively demonstrated that carboxylesterase 1 (CES1) and cathepsin A (CatA) are enzymes involved in hydrolyzing RDV to its alanine intermediate Met X, which is further hydrolyzed to the monophosphate form by histidine triad nucleotide-binding protein 1 (HINT1).	monophosphate	199-212	cathepsin A	Homo sapiens	83-87
34933885-0	2022	Contributions of Cathepsin A and Carboxylesterase 1 to the hydrolysis of Tenofovir Alafenamide in the Human Liver, and the Effect of CES1 Genetic Variation on Tenofovir Alafenamide Hydrolysis.	tenofovir alafenamide	73-94	cathepsin A	Homo sapiens	17-51
34933885-7	2022	The findings were further supported by a TAF incubation study with the CatA inhibitor telaprevir and the CES1 inhibitor bis-(p-nitrophenyl) phosphate.	telaprevir	86-96	cathepsin A	Homo sapiens	71-75
34887468-4	2021	This study aimed to elucidate the enzymes involved in GSL metabolism in lactic acid bacteria, a type of gut bacteria.	Lactic Acid	72-83	cathepsin A	Homo sapiens	54-57
34887468-5	2021	Companilactobacillus farciminis KB1089 was selected as a lactic acid bacteria strain model that metabolizes sinigrin, which is a GSL, into allylisothiocyanate.	kb1089	32-38	cathepsin A	Homo sapiens	129-132
34887468-5	2021	Companilactobacillus farciminis KB1089 was selected as a lactic acid bacteria strain model that metabolizes sinigrin, which is a GSL, into allylisothiocyanate.	Lactic Acid	57-68	cathepsin A	Homo sapiens	129-132
34887468-5	2021	Companilactobacillus farciminis KB1089 was selected as a lactic acid bacteria strain model that metabolizes sinigrin, which is a GSL, into allylisothiocyanate.	sinigrin	108-116	cathepsin A	Homo sapiens	129-132
34887468-5	2021	Companilactobacillus farciminis KB1089 was selected as a lactic acid bacteria strain model that metabolizes sinigrin, which is a GSL, into allylisothiocyanate.	allyl isothiocyanate	139-158	cathepsin A	Homo sapiens	129-132
34125594-4	2021	Our data collectively demonstrated that carboxylesterase 1 (CES1) and cathepsin A (CatA) are enzymes involved in hydrolyzing RDV to its alanine intermediate Met X, which is further hydrolyzed to the monophosphate form by histidine triad nucleotide-binding protein 1 (HINT1).	remdesivir	125-128	cathepsin A	Homo sapiens	83-87
35464721-6	2022	GSL and GSN were shown to inhibit lipid peroxidation and increase the contents of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) in human keratinocytes (HaCaTs).	Superoxides	82-92	cathepsin A	Homo sapiens	0-3
34272452-6	2021	Both gene ontology (GO) and The Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses demonstrated that CTSA co-expressed genes were involved in ATP hydrolysis coupled proton transport, carbohydrate metabolic process, lysosome organization, oxidative phosphorylation, other glycan degradation, etc.	Adenosine Triphosphate	147-150	cathepsin A	Homo sapiens	106-110
34272452-6	2021	Both gene ontology (GO) and The Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses demonstrated that CTSA co-expressed genes were involved in ATP hydrolysis coupled proton transport, carbohydrate metabolic process, lysosome organization, oxidative phosphorylation, other glycan degradation, etc.	Carbohydrates	188-200	cathepsin A	Homo sapiens	106-110
34272452-6	2021	Both gene ontology (GO) and The Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses demonstrated that CTSA co-expressed genes were involved in ATP hydrolysis coupled proton transport, carbohydrate metabolic process, lysosome organization, oxidative phosphorylation, other glycan degradation, etc.	Polysaccharides	276-282	cathepsin A	Homo sapiens	106-110
35464721-6	2022	GSL and GSN were shown to inhibit lipid peroxidation and increase the contents of superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) in human keratinocytes (HaCaTs).	Glutathione	113-124	cathepsin A	Homo sapiens	0-3
35464721-11	2022	Results indicated that the optimal formulation of GSL used soybean lecithin (SPC) as the phospholipid, with a lipid-drug ratio of 1:0.4 and a phospholipid-cholesterol ratio of 1:3.5.	Lecithins	67-75	cathepsin A	Homo sapiens	50-53
35464721-11	2022	Results indicated that the optimal formulation of GSL used soybean lecithin (SPC) as the phospholipid, with a lipid-drug ratio of 1:0.4 and a phospholipid-cholesterol ratio of 1:3.5.	Cholesterol	155-166	cathepsin A	Homo sapiens	50-53
35106939-12	2022	CONCLUSIONS: One month after completion of anthracycline treatment is the optimal time to detect cardiotoxicity by means of imaging parameters (LVESV and GSL) and to determine maximal troponin rise.	Anthracyclines	43-56	cathepsin A	Homo sapiens	154-157
3486042-9	1986	The observed changes in GSL patterns during PMA-induced differentiation of the CEM cells into suppressor-like cells and the inhibition of CEM cell growth by GM3 fractions suggest that the GSLs play a role in the control of cell growth and differentiation in the PMA-treated CEM cells.	Tetradecanoylphorbol Acetate	44-47	cathepsin A	Homo sapiens	24-27
35168327-8	2022	In conclusion, we show that GSL glycan expression levels are associated with hematopoietic AML classifications and TF and GT gene expression.	Polysaccharides	32-38	cathepsin A	Homo sapiens	28-31
3154977-1	1988	Blood platelet cathepsin A hydrolyzes Cbz-Glu-Tyr most intensively at pH 5.0, it does so too, with Cbz-Glu-Phe, but to a smaller extent.	cbz-glu-tyr	38-49	cathepsin A	Homo sapiens	15-26
3154977-1	1988	Blood platelet cathepsin A hydrolyzes Cbz-Glu-Tyr most intensively at pH 5.0, it does so too, with Cbz-Glu-Phe, but to a smaller extent.	cbz-glu	38-45	cathepsin A	Homo sapiens	15-26
3154977-1	1988	Blood platelet cathepsin A hydrolyzes Cbz-Glu-Tyr most intensively at pH 5.0, it does so too, with Cbz-Glu-Phe, but to a smaller extent.	Phenylalanine	107-110	cathepsin A	Homo sapiens	15-26
35215258-8	2022	Our results showed a different tendency of the two galectins in their binding capacities towards the glycans, depending on whether they were free oligosaccharides or as part of GSL inserted into a lipid bilayer, highlighting the significance of GSL glycan presentation on membranes in lectin binding.	Polysaccharides	101-108	cathepsin A	Homo sapiens	177-180
35215258-8	2022	Our results showed a different tendency of the two galectins in their binding capacities towards the glycans, depending on whether they were free oligosaccharides or as part of GSL inserted into a lipid bilayer, highlighting the significance of GSL glycan presentation on membranes in lectin binding.	Polysaccharides	101-108	cathepsin A	Homo sapiens	245-248
3408489-3	1988	Cathepsin A was purified from hog kidney with enzyme activity being monitored using both benzyloxycarbonyl-glutamyl-tyrosine (ZGT) and AI as substrates.	benzyloxycarbonylglutamyltyrosine	89-124	cathepsin A	Homo sapiens	0-11
3408489-7	1988	Cathepsin A,S (small) activity with ZGT or AI as substrate was inhibited to a similar extent by diisopropylfluorophosphate, mersalyl acid, and a decapeptide renin inhibitor.	Isoflurophate	96-122	cathepsin A	Homo sapiens	0-11
3408489-7	1988	Cathepsin A,S (small) activity with ZGT or AI as substrate was inhibited to a similar extent by diisopropylfluorophosphate, mersalyl acid, and a decapeptide renin inhibitor.	Mersalyl	124-137	cathepsin A	Homo sapiens	0-11
3666281-8	1987	All these GSL classes contained a high concentration (more than 20% of total acids in each class) of 2-hydroxy fatty acids.	2-hydroxy fatty acids	101-122	cathepsin A	Homo sapiens	10-13
3666281-12	1987	A minor GSL fraction (less than 1% of total neutral GSLs) which migrated more slowly than Gb5Cer on a thin layer plate and composed of several GSL components contained L-fucose.	Fucose	168-176	cathepsin A	Homo sapiens	8-11
3486042-9	1986	The observed changes in GSL patterns during PMA-induced differentiation of the CEM cells into suppressor-like cells and the inhibition of CEM cell growth by GM3 fractions suggest that the GSLs play a role in the control of cell growth and differentiation in the PMA-treated CEM cells.	Tetradecanoylphorbol Acetate	262-265	cathepsin A	Homo sapiens	24-27
6499975-7	1984	Following injections of 3H-leucine into the PPCa transported labeling is present over the entire expanse of the entorhinal cortex and is located over layer Ib with the greatest density in its superficial part.	DL-Leucine	24-34	cathepsin A	Homo sapiens	44-48
3799-1	1976	Human skeletal muscle homogenate has been shown to contain enzymes that catalyze the hydrolysis of L-leucyl p-nitroanilide and carbobenzoxyglutamyl-L-tyrosine, known substrates, respectively, for arylamidase and cathepsin A.	l-leucyl p-nitroanilide	99-122	cathepsin A	Homo sapiens	212-223
229262-7	1979	Treatment of uninfected BGM cells with cycloheximide resulted in alterations in the GSL pattern which were similar to those observed in herpes simplex virus type 1-infected cells.	Cycloheximide	39-52	cathepsin A	Homo sapiens	84-87
7020509-1	1981	To investigate whether pyrazinamide deamidase activity is suppressed in tuberculosis, serial serum concentrations of pyrazinamide, following 40 mg of pyrazinamide per kg, were determined in 10 patients with sputum positive pulmonary tuberculosis and in 10 control subjects without disease.	Pyrazinamide	23-35	cathepsin A	Homo sapiens	36-45
3799-1	1976	Human skeletal muscle homogenate has been shown to contain enzymes that catalyze the hydrolysis of L-leucyl p-nitroanilide and carbobenzoxyglutamyl-L-tyrosine, known substrates, respectively, for arylamidase and cathepsin A.	carbobenzoxyglutamyl-l-tyrosine	127-158	cathepsin A	Homo sapiens	212-223
33534538-4	2021	In the first stage, carbohydrate fragments, which contain only glycans and thus are conserved within a GSL species, are directly matched to yield a species identification.	Carbohydrates	20-32	cathepsin A	Homo sapiens	103-106
4855004-0	1974	The presence of zinc in carboxypeptidase C and coupling of the enzyme to sepharose and sephadex.	Sepharose	73-82	cathepsin A	Homo sapiens	24-42
4855004-0	1974	The presence of zinc in carboxypeptidase C and coupling of the enzyme to sepharose and sephadex.	sephadex	87-95	cathepsin A	Homo sapiens	24-42
5699463-0	1968	[Cleavage of proline bonds by carboxypeptidase C].	Proline	13-20	cathepsin A	Homo sapiens	30-48
4326747-1	1971	I. Nicotinamide mononucleotide deamidase and a new pathway for "salvage synthesis" of nicotinamide adenine dinucleotide].	NAD	86-119	cathepsin A	Homo sapiens	31-40
33534538-5	2021	In the second stage, glycolipid fragments from the matched GSL species, which contain both the lipid and glycans and thus shift due to lipid structural changes, are treated according to lipid rule-based matching to characterize the lipid compositions.	Glycolipids	21-31	cathepsin A	Homo sapiens	59-62
33534538-5	2021	In the second stage, glycolipid fragments from the matched GSL species, which contain both the lipid and glycans and thus shift due to lipid structural changes, are treated according to lipid rule-based matching to characterize the lipid compositions.	Polysaccharides	105-112	cathepsin A	Homo sapiens	59-62
33139318-7	2021	The levels of mRNA for the NEU1 chaperone, protective protein/cathepsin A (PPCA), were also elevated by bleomycin.	Bleomycin	104-113	cathepsin A	Homo sapiens	43-73
33673393-5	2021	A shift of the dominant phospholipid phosphatidylcholine with saturated fatty acids in the DRM to unsaturated species in the non-DRM fractions correlated with the GSL distribution.	Phospholipids	24-36	cathepsin A	Homo sapiens	163-166
33673393-5	2021	A shift of the dominant phospholipid phosphatidylcholine with saturated fatty acids in the DRM to unsaturated species in the non-DRM fractions correlated with the GSL distribution.	Phosphatidylcholines	37-56	cathepsin A	Homo sapiens	163-166
33673393-5	2021	A shift of the dominant phospholipid phosphatidylcholine with saturated fatty acids in the DRM to unsaturated species in the non-DRM fractions correlated with the GSL distribution.	Fatty Acids	62-83	cathepsin A	Homo sapiens	163-166
33395290-2	2021	This strategy was highlighted by using a simple lactoside containing the core structures of GSL glycan and lipid as the universal starting material to obtain different synthetic targets upon stepwise elongation of the glycan via chemical glycosylations and on-site remodeling of the lipid via chemoselective cross-metathesis and N-acylation.	lactosides	48-57	cathepsin A	Homo sapiens	92-95
33395290-2	2021	This strategy was highlighted by using a simple lactoside containing the core structures of GSL glycan and lipid as the universal starting material to obtain different synthetic targets upon stepwise elongation of the glycan via chemical glycosylations and on-site remodeling of the lipid via chemoselective cross-metathesis and N-acylation.	Polysaccharides	96-102	cathepsin A	Homo sapiens	92-95
33395290-3	2021	The strategy was verified with the synthesis of a lacto-ganglio GSL, LcGg4, which is a biomarker of undifferentiated malignant myeloid cells, and a series of its analogues or derivatives carrying different sugar chains and unique functionalities or molecular labels.	lactogangliotetraosylceramide	69-74	cathepsin A	Homo sapiens	64-67
32860713-3	2020	Here, we focus on GD2, a disialoganglioside expressed in tumors of neuroectodermal origin, and Globo H ceramide, the most prevalent cancer-associated GSL overexpressed in a variety of epithelial cancers.	h ceramide	101-111	cathepsin A	Homo sapiens	150-153
32900381-7	2020	For glycosphingolipids (GSLs), Globo H ceramide, an important tumor-associated GSL which is being actively investigated as a target for new cancer immunotherapies, will be used to demonstrate how glycan structure plays a significant role in enhancing angiogenesis in tumor microenvironments.	Ceramides	39-47	cathepsin A	Homo sapiens	24-27
33126541-2	2020	We explored the ultrafast time-scale limits of photo-induced charge transfer between a Ru(II)tris(bipyridine) derivative photosensitizer and PpcA, a 3-heme c-type cytochrome serving as a nanoscale biological wire.	ru(ii)tris	87-97	cathepsin A	Homo sapiens	141-145
33126541-2	2020	We explored the ultrafast time-scale limits of photo-induced charge transfer between a Ru(II)tris(bipyridine) derivative photosensitizer and PpcA, a 3-heme c-type cytochrome serving as a nanoscale biological wire.	2,2'-Dipyridyl	98-108	cathepsin A	Homo sapiens	141-145
32883073-6	2020	In brief, deprotonated GSL anions, [GSL-H]-, and terpyridine-magnesium complex dications, [Mg(Terpy)2]2+, are sequentially injected and mutually stored in a linear ion trap to form charge-inverted complex cations, [GSL-H + MgTerpy]+.	gsl-h	36-41	cathepsin A	Homo sapiens	23-26
32883073-6	2020	In brief, deprotonated GSL anions, [GSL-H]-, and terpyridine-magnesium complex dications, [Mg(Terpy)2]2+, are sequentially injected and mutually stored in a linear ion trap to form charge-inverted complex cations, [GSL-H + MgTerpy]+.	gsl-h	215-220	cathepsin A	Homo sapiens	23-26
32883073-6	2020	In brief, deprotonated GSL anions, [GSL-H]-, and terpyridine-magnesium complex dications, [Mg(Terpy)2]2+, are sequentially injected and mutually stored in a linear ion trap to form charge-inverted complex cations, [GSL-H + MgTerpy]+.	mgterpy	223-230	cathepsin A	Homo sapiens	23-26
32727849-4	2020	Here, we demonstrate that beta-Gal negatively regulates NEU1 levels in lysosomes by competitively displacing this labile sialidase from PPCA.	cyclohexenoesculetin-beta-galactoside	30-34	cathepsin A	Homo sapiens	136-140
32900381-7	2020	For glycosphingolipids (GSLs), Globo H ceramide, an important tumor-associated GSL which is being actively investigated as a target for new cancer immunotherapies, will be used to demonstrate how glycan structure plays a significant role in enhancing angiogenesis in tumor microenvironments.	Polysaccharides	196-202	cathepsin A	Homo sapiens	24-27
32187230-8	2020	A pilot study treating MRL/lpr females with GlcCer synthase inhibitor Genz-667161 to block GSL synthesis resulted in a strong significant negative correlation between Genz-667161 dose and renal GSL hexosylceramide and GM3 levels.	genz-667161	70-81	cathepsin A	Homo sapiens	91-94
32551569-9	2020	Realizing lack of information on the regulation of GSL biosynthesis and degradation mechanism, this review also includes those information along with their connection with crosstalks between various factors, such as light, sulfur metabolism, and nitrogen metabolism, with the GSL biosynthesis as means to provide a comprehensive reference for other crucifer species.	Sulfur	223-229	cathepsin A	Homo sapiens	276-279
32551569-9	2020	Realizing lack of information on the regulation of GSL biosynthesis and degradation mechanism, this review also includes those information along with their connection with crosstalks between various factors, such as light, sulfur metabolism, and nitrogen metabolism, with the GSL biosynthesis as means to provide a comprehensive reference for other crucifer species.	Nitrogen	246-254	cathepsin A	Homo sapiens	276-279
32305437-0	2020	Structural and Kinetic Evidence of Aging after Organophosphate Inhibition of Human Cathepsin A.	Organophosphates	47-62	cathepsin A	Homo sapiens	83-94
32305437-1	2020	Human Cathepsin A (CatA) is a lysosomal serine carboxypeptidase of the renin-angiotensin system (RAS) and is structurally similar to acetylcholinesterase (AChE).	Serine	40-46	cathepsin A	Homo sapiens	6-17
32305437-1	2020	Human Cathepsin A (CatA) is a lysosomal serine carboxypeptidase of the renin-angiotensin system (RAS) and is structurally similar to acetylcholinesterase (AChE).	Serine	40-46	cathepsin A	Homo sapiens	19-23
32305437-2	2020	CatA can remove the C-terminal amino acids of endothelin I, angiotensin I, Substance P, oxytocin, and bradykinin, and can deamidate neurokinin A. Proteomic studies identified CatA and its homologue SCPEP1 as potential targets of organophosphates (OP).	Oxytocin	88-96	cathepsin A	Homo sapiens	0-4
32305437-2	2020	CatA can remove the C-terminal amino acids of endothelin I, angiotensin I, Substance P, oxytocin, and bradykinin, and can deamidate neurokinin A. Proteomic studies identified CatA and its homologue SCPEP1 as potential targets of organophosphates (OP).	Organophosphates	229-245	cathepsin A	Homo sapiens	0-4
32305437-2	2020	CatA can remove the C-terminal amino acids of endothelin I, angiotensin I, Substance P, oxytocin, and bradykinin, and can deamidate neurokinin A. Proteomic studies identified CatA and its homologue SCPEP1 as potential targets of organophosphates (OP).	Organophosphates	229-245	cathepsin A	Homo sapiens	175-179
32305437-3	2020	CatA could be stably inhibited by low microM to high nM concentrations of racemic sarin (GB), soman (GD), cyclosarin (GF), VX, and VR within minutes to hours at pH 7.	Sarin	82-87	cathepsin A	Homo sapiens	0-4
32305437-3	2020	CatA could be stably inhibited by low microM to high nM concentrations of racemic sarin (GB), soman (GD), cyclosarin (GF), VX, and VR within minutes to hours at pH 7.	Soman	94-99	cathepsin A	Homo sapiens	0-4
32305437-3	2020	CatA could be stably inhibited by low microM to high nM concentrations of racemic sarin (GB), soman (GD), cyclosarin (GF), VX, and VR within minutes to hours at pH 7.	Gadolinium	101-103	cathepsin A	Homo sapiens	0-4
32305437-3	2020	CatA could be stably inhibited by low microM to high nM concentrations of racemic sarin (GB), soman (GD), cyclosarin (GF), VX, and VR within minutes to hours at pH 7.	cyclohexyl methylphosphonofluoridate	106-116	cathepsin A	Homo sapiens	0-4
32305437-6	2020	Notably, both AChE and CatA bound diisopropylfluorophosphate (DFP) comparably and had KIDFP = 13 microM and 11 microM, respectively.	Isoflurophate	34-60	cathepsin A	Homo sapiens	23-27
32305437-6	2020	Notably, both AChE and CatA bound diisopropylfluorophosphate (DFP) comparably and had KIDFP = 13 microM and 11 microM, respectively.	Isoflurophate	62-65	cathepsin A	Homo sapiens	23-27
32305437-8	2020	At pH 6.5 CatA remained stably inhibited by GB and GF and <10% of the enzyme spontaneously reactivated after 200 h. A crystal structure of DFP-inhibited CatA was determined and contained an aged adduct.	Isoflurophate	139-142	cathepsin A	Homo sapiens	10-14
32305437-8	2020	At pH 6.5 CatA remained stably inhibited by GB and GF and <10% of the enzyme spontaneously reactivated after 200 h. A crystal structure of DFP-inhibited CatA was determined and contained an aged adduct.	Isoflurophate	139-142	cathepsin A	Homo sapiens	153-157
32515700-13	2020	The presence of PSS associated with decreased GSL may indicate multivascular IHD.	pss	16-19	cathepsin A	Homo sapiens	46-49
32961778-3	2020	Of the hundreds of unique GSL structures, anionic gangliosides are the most heavily implicated in the pathogenesis of lysosomal storage diseases (LSDs) such as Tay-Sachs and Sandhoff disease.	Gangliosides	50-62	cathepsin A	Homo sapiens	26-29
32592726-8	2020	Here, we review current knowledge about deregulated GSL species in cancer, GSL influence on glutamine and glucose metabolism.	Glutamine	92-101	cathepsin A	Homo sapiens	75-78
32187230-8	2020	A pilot study treating MRL/lpr females with GlcCer synthase inhibitor Genz-667161 to block GSL synthesis resulted in a strong significant negative correlation between Genz-667161 dose and renal GSL hexosylceramide and GM3 levels.	genz-667161	167-178	cathepsin A	Homo sapiens	91-94
31771325-10	2020	Hematoxylin &amp; Eosin, Masson"s trichrome and Picrosirius red staining showed better regeneration and collagen remodeling in ADSCs loaded GSL scaffolds.	Hematoxylin	0-11	cathepsin A	Homo sapiens	140-143
31944669-3	2020	Recently, it was suggested that, when present together with high affinity ligands, low affinity GSL ligands can contribute significantly to the binding of GBPs with multiple binding sites through a process called heteromultivalent binding.	gbps	155-159	cathepsin A	Homo sapiens	96-99
31944669-4	2020	Here, with goal of directly establishing the existence of heteromultivalent GSL interactions and elucidating the mechanism underlying their formation, we investigated cholera toxin B subunit homopentamer (CTB5) binding to ganglioside mixtures in model membranes (nanodiscs) using native mass spectrometry (MS) and competitive ligand binding.	Gangliosides	222-233	cathepsin A	Homo sapiens	76-79
31148289-7	2019	We demonstrate an interaction between Glbs and ABA on several grounds: Glb1 and Glb2 scavenge NO produced in stomatal guard cells following ABA supply; plants overexpressing Glb1 show higher constitutive expression of the ABA responsive genes Responsive to ABA (RAB18), Responsive to Dehydration (RD29A) and Highly ABA-Induced 2 (HAI2), and are more tolerant to dehydration; and ABA strongly upregulates class 1 Glbs.	Abscisic Acid	47-50	cathepsin A	Homo sapiens	80-84
31192586-2	2019	Counterintuitively, crystal structures of CatA and its homologues show a cluster of Glu and Asp residues binding the C-terminal carboxylic acid of the product or inhibitor.	Glutamic Acid	84-87	cathepsin A	Homo sapiens	42-46
31192586-2	2019	Counterintuitively, crystal structures of CatA and its homologues show a cluster of Glu and Asp residues binding the C-terminal carboxylic acid of the product or inhibitor.	Aspartic Acid	92-95	cathepsin A	Homo sapiens	42-46
31192586-2	2019	Counterintuitively, crystal structures of CatA and its homologues show a cluster of Glu and Asp residues binding the C-terminal carboxylic acid of the product or inhibitor.	Carboxylic Acids	128-143	cathepsin A	Homo sapiens	42-46
31192586-7	2019	In CatA, E69 and E149 form a Glu pair that is important to catalysis as evidenced by the 56-fold decrease in kcat/Km in the E69Q/E149Q variant.	Glutamic Acid	29-32	cathepsin A	Homo sapiens	3-7
31798608-11	2019	We compared the effect of root herbivore damage on the expression of GSL biosynthesis (CYP79A1, CYP83B2), transporter (GTR1A2, GTR2A2), and GSL hydrolysis genes (PEN2, TGG2) in roots of low and high GSL varieties in conjugation with their GSL levels.	enkephalinamide, Pen(2)-Cys(5)-	162-166	cathepsin A	Homo sapiens	69-72
31798608-12	2019	We found that roots of high GSL varieties contained higher levels of aliphatic, indole, and benzyl GSLs than low GSL varieties.	indole	80-86	cathepsin A	Homo sapiens	28-31
31798608-12	2019	We found that roots of high GSL varieties contained higher levels of aliphatic, indole, and benzyl GSLs than low GSL varieties.	benzyl 2,3,4-tri-O-benzylglucopyranoside	92-98	cathepsin A	Homo sapiens	28-31
31798608-12	2019	We found that roots of high GSL varieties contained higher levels of aliphatic, indole, and benzyl GSLs than low GSL varieties.	benzyl 2,3,4-tri-O-benzylglucopyranoside	92-98	cathepsin A	Homo sapiens	99-102
31798608-12	2019	We found that roots of high GSL varieties contained higher levels of aliphatic, indole, and benzyl GSLs than low GSL varieties.	Glucosinolates	99-103	cathepsin A	Homo sapiens	28-31
31798608-13	2019	Infestation with D. radicum larvae led to upregulation of indole GSL synthesis genes in low and high GSL varieties.	indole	58-64	cathepsin A	Homo sapiens	65-68
31798608-13	2019	Infestation with D. radicum larvae led to upregulation of indole GSL synthesis genes in low and high GSL varieties.	indole	58-64	cathepsin A	Homo sapiens	101-104
31294768-13	2019	Forty patients were randomized to the PEI group and 38 to the PEI-GSL group.	pei	62-65	cathepsin A	Homo sapiens	66-69
31294768-14	2019	The mean (SD) IOP at baseline was 22.3 (8.5) mm Hg for the PEI group and 22.9 (5.3) mm Hg for the PEI-GSL group.	pei	98-101	cathepsin A	Homo sapiens	102-105
31294768-15	2019	At 1 year, the mean IOP was 14.3 (5.0) mm Hg for the PEI group and 15.9 (4.5) mm Hg for the PEI-GSL group.	pei	92-95	cathepsin A	Homo sapiens	96-99
31148289-7	2019	We demonstrate an interaction between Glbs and ABA on several grounds: Glb1 and Glb2 scavenge NO produced in stomatal guard cells following ABA supply; plants overexpressing Glb1 show higher constitutive expression of the ABA responsive genes Responsive to ABA (RAB18), Responsive to Dehydration (RD29A) and Highly ABA-Induced 2 (HAI2), and are more tolerant to dehydration; and ABA strongly upregulates class 1 Glbs.	Abscisic Acid	140-143	cathepsin A	Homo sapiens	80-84
31148289-7	2019	We demonstrate an interaction between Glbs and ABA on several grounds: Glb1 and Glb2 scavenge NO produced in stomatal guard cells following ABA supply; plants overexpressing Glb1 show higher constitutive expression of the ABA responsive genes Responsive to ABA (RAB18), Responsive to Dehydration (RD29A) and Highly ABA-Induced 2 (HAI2), and are more tolerant to dehydration; and ABA strongly upregulates class 1 Glbs.	Abscisic Acid	140-143	cathepsin A	Homo sapiens	80-84
31148289-7	2019	We demonstrate an interaction between Glbs and ABA on several grounds: Glb1 and Glb2 scavenge NO produced in stomatal guard cells following ABA supply; plants overexpressing Glb1 show higher constitutive expression of the ABA responsive genes Responsive to ABA (RAB18), Responsive to Dehydration (RD29A) and Highly ABA-Induced 2 (HAI2), and are more tolerant to dehydration; and ABA strongly upregulates class 1 Glbs.	Abscisic Acid	140-143	cathepsin A	Homo sapiens	80-84
31148289-7	2019	We demonstrate an interaction between Glbs and ABA on several grounds: Glb1 and Glb2 scavenge NO produced in stomatal guard cells following ABA supply; plants overexpressing Glb1 show higher constitutive expression of the ABA responsive genes Responsive to ABA (RAB18), Responsive to Dehydration (RD29A) and Highly ABA-Induced 2 (HAI2), and are more tolerant to dehydration; and ABA strongly upregulates class 1 Glbs.	Abscisic Acid	140-143	cathepsin A	Homo sapiens	80-84
31148289-7	2019	We demonstrate an interaction between Glbs and ABA on several grounds: Glb1 and Glb2 scavenge NO produced in stomatal guard cells following ABA supply; plants overexpressing Glb1 show higher constitutive expression of the ABA responsive genes Responsive to ABA (RAB18), Responsive to Dehydration (RD29A) and Highly ABA-Induced 2 (HAI2), and are more tolerant to dehydration; and ABA strongly upregulates class 1 Glbs.	Abscisic Acid	140-143	cathepsin A	Homo sapiens	80-84
30278264-0	2019	The Relationship between the Concentration of Cathepsin A, D, and E and the Concentration of Copper and Zinc, and the Size of the Aneurysmal Enlargement in the Wall of the Abdominal Aortic Aneurysm.	Copper	93-99	cathepsin A	Homo sapiens	46-67
30942930-5	2019	The APB GSL correlated with electromyographic severity and disease duration (rho = 0.46, P < 0.001 and rho = 0.45, P = 0.003).	apb	4-7	cathepsin A	Homo sapiens	8-11
31148289-7	2019	We demonstrate an interaction between Glbs and ABA on several grounds: Glb1 and Glb2 scavenge NO produced in stomatal guard cells following ABA supply; plants overexpressing Glb1 show higher constitutive expression of the ABA responsive genes Responsive to ABA (RAB18), Responsive to Dehydration (RD29A) and Highly ABA-Induced 2 (HAI2), and are more tolerant to dehydration; and ABA strongly upregulates class 1 Glbs.	glbs	38-42	cathepsin A	Homo sapiens	80-84
31353882-3	2019	To address this challenge, we developed a novel strategy for analysis of GSL-glycans from cultured cells based on a lectin microarray that can directly detect and reveal glycopatterns of GSL extracts without the need for glycan release.	Polysaccharides	77-83	cathepsin A	Homo sapiens	73-76
31353882-4	2019	There were six steps to perform the analysis of GSL-glycans: (i) extraction of GSLs from cell pellets, (ii) quantification of GSL-glycans using orcinol-sulfuric acid reaction, (iii) preparation of lyso-GSLs by using sphingolipid ceramide N-deacylase, (iv) fluorescence labeling of lyso-GSLs, (v) detection by a lectin microarray, (vi) data acquisition and analysis.	Glycosphingolipids	79-83	cathepsin A	Homo sapiens	48-51
31353882-4	2019	There were six steps to perform the analysis of GSL-glycans: (i) extraction of GSLs from cell pellets, (ii) quantification of GSL-glycans using orcinol-sulfuric acid reaction, (iii) preparation of lyso-GSLs by using sphingolipid ceramide N-deacylase, (iv) fluorescence labeling of lyso-GSLs, (v) detection by a lectin microarray, (vi) data acquisition and analysis.	sulfuric acid	152-165	cathepsin A	Homo sapiens	48-51
31353882-4	2019	There were six steps to perform the analysis of GSL-glycans: (i) extraction of GSLs from cell pellets, (ii) quantification of GSL-glycans using orcinol-sulfuric acid reaction, (iii) preparation of lyso-GSLs by using sphingolipid ceramide N-deacylase, (iv) fluorescence labeling of lyso-GSLs, (v) detection by a lectin microarray, (vi) data acquisition and analysis.	lyso-gsls	197-206	cathepsin A	Homo sapiens	48-51
31353882-4	2019	There were six steps to perform the analysis of GSL-glycans: (i) extraction of GSLs from cell pellets, (ii) quantification of GSL-glycans using orcinol-sulfuric acid reaction, (iii) preparation of lyso-GSLs by using sphingolipid ceramide N-deacylase, (iv) fluorescence labeling of lyso-GSLs, (v) detection by a lectin microarray, (vi) data acquisition and analysis.	lyso-gsls	281-290	cathepsin A	Homo sapiens	48-51
31179689-5	2019	Here, we present a workflow for the analysis of procainamide-labeled GSL glycans using HILIC-IM-MS and a new, automated glycan identification strategy whereby multiple glycan attributes are combined to increase accuracy in automated structural assignments.	Procainamide	48-60	cathepsin A	Homo sapiens	69-72
31179689-5	2019	Here, we present a workflow for the analysis of procainamide-labeled GSL glycans using HILIC-IM-MS and a new, automated glycan identification strategy whereby multiple glycan attributes are combined to increase accuracy in automated structural assignments.	Polysaccharides	73-79	cathepsin A	Homo sapiens	69-72
31179689-6	2019	For glycan matching and identification, an experimental reference database of GSL glycans containing GU, mass, and CCS values for each glycan was created.	Polysaccharides	82-88	cathepsin A	Homo sapiens	78-81
31058489-3	2019	Here, we describe the development of a novel and high-throughput-compatible workflow for the analysis of GSL-derived glycans based on ceramide glycanase digestion, 8-aminopyrene-1,3,6-trisulfonic acid (APTS) labeling, and multiplexed capillary gel electrophoresis coupled to laser-induced fluorescence detection (xCGE-LIF).	Polysaccharides	117-124	cathepsin A	Homo sapiens	105-108
31058489-3	2019	Here, we describe the development of a novel and high-throughput-compatible workflow for the analysis of GSL-derived glycans based on ceramide glycanase digestion, 8-aminopyrene-1,3,6-trisulfonic acid (APTS) labeling, and multiplexed capillary gel electrophoresis coupled to laser-induced fluorescence detection (xCGE-LIF).	Ceramides	134-142	cathepsin A	Homo sapiens	105-108
31058489-3	2019	Here, we describe the development of a novel and high-throughput-compatible workflow for the analysis of GSL-derived glycans based on ceramide glycanase digestion, 8-aminopyrene-1,3,6-trisulfonic acid (APTS) labeling, and multiplexed capillary gel electrophoresis coupled to laser-induced fluorescence detection (xCGE-LIF).	8-aminopyrene-1,3,6-trisulfonic acid	164-200	cathepsin A	Homo sapiens	105-108
30278264-2	2019	The aim of this study is to determine the relationship between the concentration of lysosomal peptidases cathepsin A, D, and E in the wall of the abdominal aortic aneurysm and the concentration of copper and zinc, and the size of the aneurysm widening in the wall of the abdominal aortic aneurysm.	Copper	197-203	cathepsin A	Homo sapiens	105-126
30030471-3	2018	The method provides the composition and sequence of the glycan, as well as variations in the ceramide portion of the GSL.	Ceramides	93-101	cathepsin A	Homo sapiens	117-120
30204045-14	2019	Spontaneous CD62P and PAC1 expression were significantly greater, and ADP-induced aggregation and agonist-induced increase in CD62P and PAC1 were significantly lower in PPCA compared to APC and PPC on day 4 of storage.	Adenosine Diphosphate	70-73	cathepsin A	Homo sapiens	169-173
30204045-15	2019	ADP and TRAP-induced CD62P and PAC1 activatability fell significantly during storage between day 1 and day 4 in APC and PPCA, but not in PPC.	Adenosine Diphosphate	0-3	cathepsin A	Homo sapiens	120-124
30284662-5	2018	The minor GSL components were effectively purified despite both sources containing tremendous amount of phospholipids and simple lipids such as cholesterol, cholesteryl esters and triglycerides.	Phospholipids	104-117	cathepsin A	Homo sapiens	10-13
30284662-5	2018	The minor GSL components were effectively purified despite both sources containing tremendous amount of phospholipids and simple lipids such as cholesterol, cholesteryl esters and triglycerides.	Cholesterol	144-155	cathepsin A	Homo sapiens	10-13
30284662-5	2018	The minor GSL components were effectively purified despite both sources containing tremendous amount of phospholipids and simple lipids such as cholesterol, cholesteryl esters and triglycerides.	Cholesterol Esters	157-175	cathepsin A	Homo sapiens	10-13
30284662-5	2018	The minor GSL components were effectively purified despite both sources containing tremendous amount of phospholipids and simple lipids such as cholesterol, cholesteryl esters and triglycerides.	Triglycerides	180-193	cathepsin A	Homo sapiens	10-13
30010039-2	2018	In a certain number of galactosialidosis patients, a base substitution from adenine to guanine is observed at the +3 position of the 7th intron (IVS7 +3a&gt;g) of the CTSA gene.	Adenine	76-83	cathepsin A	Homo sapiens	167-171
30010039-2	2018	In a certain number of galactosialidosis patients, a base substitution from adenine to guanine is observed at the +3 position of the 7th intron (IVS7 +3a&gt;g) of the CTSA gene.	Guanine	87-94	cathepsin A	Homo sapiens	167-171
29966919-11	2018	CONCLUSIONS: Accidental heroin overdose emergency department visits and inpatient hospital admissions increased in New York State after the enactment of the 911 GSL, consistent with the intended effect of the GSL.	Heroin	24-30	cathepsin A	Homo sapiens	161-164
29966919-11	2018	CONCLUSIONS: Accidental heroin overdose emergency department visits and inpatient hospital admissions increased in New York State after the enactment of the 911 GSL, consistent with the intended effect of the GSL.	Heroin	24-30	cathepsin A	Homo sapiens	209-212
29962464-7	2018	Human cathepsin A (Ctsa) precursor proteins purified from the cocoons have been found to suppress microglial activation in the brains of Ctsa-deficient mice; this deficiency is caused by a splicing defect, and serves as a galactosialidosis model associated with the combination of a deficiency of lysosomal neuraminidase 1 (NEU1) and the accumulation of sialyloligosaccharides.	sialooligosaccharides	354-376	cathepsin A	Homo sapiens	6-17
30637700-9	2018	The apoptosis-inducing agent (e.g., cis-platin) showed inhibition of DNA polymerase/helicase (part of the replisomes) and also modulated (positively) a few glycolipid-glycosyltransferase (GSL-GLTs) transcriptions in the early stages (within 2 h after treatment) of apoptosis.	Cisplatin	36-46	cathepsin A	Homo sapiens	188-191
29539397-5	2018	Our findings indicate that GSL-containing mixtures, regardless of the carbohydrate size, enhance the ordering of the surrounding lipids, resulting in a larger fraction of ordered phase of the monolayer and greater dimensions of the ordered domains.	Carbohydrates	70-82	cathepsin A	Homo sapiens	27-30
29491402-8	2018	We will focus on the lipid components of the MAMs, and highlight how failure to digest or process the sialylated GSL, GM1 ganglioside, in lysosomes alters the lipid conformation and functional properties of the MAMs and leads to neuronal cell death and neurodegeneration.	G(M1) Ganglioside	118-133	cathepsin A	Homo sapiens	113-116
29962464-7	2018	Human cathepsin A (Ctsa) precursor proteins purified from the cocoons have been found to suppress microglial activation in the brains of Ctsa-deficient mice; this deficiency is caused by a splicing defect, and serves as a galactosialidosis model associated with the combination of a deficiency of lysosomal neuraminidase 1 (NEU1) and the accumulation of sialyloligosaccharides.	sialooligosaccharides	354-376	cathepsin A	Homo sapiens	19-23
29312937-6	2017	Based on their catalytic active site residue, the 15 human cathepsins identified up to now are classified in three different families: serine (cathepsins A and G), aspartate (cathepsins D and E), or cysteine (cathepsins B, C, F, H, K, L, O, S, V, X, and W) proteases.	Serine	135-141	cathepsin A	Homo sapiens	143-161
28400374-9	2017	Medication use and extent of PAS only reduced with phaco-GSL, from 0.923+-0.86 to 0.384+-0.18 medications, p=0.0279, and from 249.2+-83.4 to 110.8+-53.9  PAS, 6 months postoperatively.	Aminosalicylic Acid	29-32	cathepsin A	Homo sapiens	57-60
27549315-12	2017	Finally, unique GSL signatures in ES and cancer cells are exploited in glycan-targeted anti-cancer immunotherapy and their mechanistic investigations were discussed using anti-GD2 mAb and Globo H as examples.	Polysaccharides	71-77	cathepsin A	Homo sapiens	16-19
29503735-7	2017	PBRN Directors identified greater CTSA effectiveness in PBRN engagement, consultation, and collaborative grant submissions.	pbrn	0-4	cathepsin A	Homo sapiens	34-38
28400374-9	2017	Medication use and extent of PAS only reduced with phaco-GSL, from 0.923+-0.86 to 0.384+-0.18 medications, p=0.0279, and from 249.2+-83.4 to 110.8+-53.9  PAS, 6 months postoperatively.	Aminosalicylic Acid	154-157	cathepsin A	Homo sapiens	57-60
28400374-12	2017	However, only eyes undergoing GSL combined with standard phacoemulsification had significantly increased TOF, reduced glaucoma medication dependence and PAS postoperatively.	Aminosalicylic Acid	153-156	cathepsin A	Homo sapiens	30-33
28327633-7	2017	Cathepsin A (CatA) inhibitors attenuated L-ala,SP prodrug metabolite formation, yet exacerbated L-ala,SP + amiodarone effects, implicating the prodrugs in these effects.	polyalanine	41-46	cathepsin A	Homo sapiens	0-11
28327633-7	2017	Cathepsin A (CatA) inhibitors attenuated L-ala,SP prodrug metabolite formation, yet exacerbated L-ala,SP + amiodarone effects, implicating the prodrugs in these effects.	polyalanine	41-46	cathepsin A	Homo sapiens	13-17
28327633-7	2017	Cathepsin A (CatA) inhibitors attenuated L-ala,SP prodrug metabolite formation, yet exacerbated L-ala,SP + amiodarone effects, implicating the prodrugs in these effects.	TFF2 protein, human	47-49	cathepsin A	Homo sapiens	0-11
28327633-7	2017	Cathepsin A (CatA) inhibitors attenuated L-ala,SP prodrug metabolite formation, yet exacerbated L-ala,SP + amiodarone effects, implicating the prodrugs in these effects.	TFF2 protein, human	47-49	cathepsin A	Homo sapiens	13-17
28327633-7	2017	Cathepsin A (CatA) inhibitors attenuated L-ala,SP prodrug metabolite formation, yet exacerbated L-ala,SP + amiodarone effects, implicating the prodrugs in these effects.	polyalanine	96-101	cathepsin A	Homo sapiens	0-11
28327633-7	2017	Cathepsin A (CatA) inhibitors attenuated L-ala,SP prodrug metabolite formation, yet exacerbated L-ala,SP + amiodarone effects, implicating the prodrugs in these effects.	polyalanine	96-101	cathepsin A	Homo sapiens	13-17
28327633-7	2017	Cathepsin A (CatA) inhibitors attenuated L-ala,SP prodrug metabolite formation, yet exacerbated L-ala,SP + amiodarone effects, implicating the prodrugs in these effects.	TFF2 protein, human	102-104	cathepsin A	Homo sapiens	0-11
28327633-7	2017	Cathepsin A (CatA) inhibitors attenuated L-ala,SP prodrug metabolite formation, yet exacerbated L-ala,SP + amiodarone effects, implicating the prodrugs in these effects.	TFF2 protein, human	102-104	cathepsin A	Homo sapiens	13-17
28327633-7	2017	Cathepsin A (CatA) inhibitors attenuated L-ala,SP prodrug metabolite formation, yet exacerbated L-ala,SP + amiodarone effects, implicating the prodrugs in these effects.	Amiodarone	107-117	cathepsin A	Homo sapiens	0-11
28327633-7	2017	Cathepsin A (CatA) inhibitors attenuated L-ala,SP prodrug metabolite formation, yet exacerbated L-ala,SP + amiodarone effects, implicating the prodrugs in these effects.	Amiodarone	107-117	cathepsin A	Homo sapiens	13-17
27999995-9	2017	With respect to infections, various GSL-presented glycans are attachment sites for bacteria and viruses as well as primary targets for bacterial toxins.	Polysaccharides	50-57	cathepsin A	Homo sapiens	36-39
26407609-7	2016	Importantly, we find that antibody-mediated cross-linking of Gb3 and GM1, the GSL receptors for Shiga and cholera toxin, respectively, also induces dissociation.	G(M1) Ganglioside	69-72	cathepsin A	Homo sapiens	78-81
27363608-9	2016	In conclusion, this FLUX lipidomics experimental approach with the addition of [13C-U]glucose to cells allows us to not only study the total turnover but also permit observations of lipid intermediates and metabolic flow of endogenous GSL species at the molecular lipid level.	13c	80-83	cathepsin A	Homo sapiens	235-238
27363608-9	2016	In conclusion, this FLUX lipidomics experimental approach with the addition of [13C-U]glucose to cells allows us to not only study the total turnover but also permit observations of lipid intermediates and metabolic flow of endogenous GSL species at the molecular lipid level.	Glucose	86-93	cathepsin A	Homo sapiens	235-238
27806280-3	2016	To gain molecular insight into the organization and dynamics of GSL-rich membranes, we performed all-atom molecular-dynamics simulations of bicomponent ganglioside GM1 in 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) phospholipid bilayers with varying concentrations of GM1 (10%, 20%, and 30%).	G(M1) Ganglioside	164-167	cathepsin A	Homo sapiens	64-67
27626296-2	2016	GM-3 ganglioside, a widespread GSL, affects HIV entry and infection in different ways, depending on the concentration, through its anchoring activity in lipid rafts.	G(M3) Ganglioside	0-16	cathepsin A	Homo sapiens	31-34
27033327-5	2016	The workflow features enzymatic release of GSL glycans with a novel broad-specificity endoglycoceramidase I (EGCase I) from Rhodococcus triatomea, selective glycan capture on hydrazide beads on a robotics platform, 2AB-fluorescent glycan labeling, and analysis by UPLC-HILIC-FLD.	Polysaccharides	47-53	cathepsin A	Homo sapiens	43-46
27033327-5	2016	The workflow features enzymatic release of GSL glycans with a novel broad-specificity endoglycoceramidase I (EGCase I) from Rhodococcus triatomea, selective glycan capture on hydrazide beads on a robotics platform, 2AB-fluorescent glycan labeling, and analysis by UPLC-HILIC-FLD.	Isoniazid	175-184	cathepsin A	Homo sapiens	43-46
27033327-5	2016	The workflow features enzymatic release of GSL glycans with a novel broad-specificity endoglycoceramidase I (EGCase I) from Rhodococcus triatomea, selective glycan capture on hydrazide beads on a robotics platform, 2AB-fluorescent glycan labeling, and analysis by UPLC-HILIC-FLD.	Polysaccharides	157-163	cathepsin A	Homo sapiens	43-46
26800360-5	2016	The results reveal that RDD can quantitatively distinguish lyso-GSL epimers without the requirement of prior separation by liquid chromatography.	lyso	59-63	cathepsin A	Homo sapiens	64-67
26405105-6	2016	Supplementation with the isoprenoid precursor, geranylgeranyl pyrophosphate (GGPP), a downstream product of HMG Co-A reductase, reversed statin-induced glycosyltransferase and GSL elevation.	Terpenes	25-35	cathepsin A	Homo sapiens	176-179
26405105-6	2016	Supplementation with the isoprenoid precursor, geranylgeranyl pyrophosphate (GGPP), a downstream product of HMG Co-A reductase, reversed statin-induced glycosyltransferase and GSL elevation.	geranylgeranyl pyrophosphate	47-75	cathepsin A	Homo sapiens	176-179
26405105-6	2016	Supplementation with the isoprenoid precursor, geranylgeranyl pyrophosphate (GGPP), a downstream product of HMG Co-A reductase, reversed statin-induced glycosyltransferase and GSL elevation.	geranylgeranyl pyrophosphate	77-81	cathepsin A	Homo sapiens	176-179
26405105-9	2016	GSL-dependent vesicular retrograde transport of Verotoxin and cholera toxin to the Golgi/endoplasmic reticulum were blocked after statin or 3-PEHPC treatment, suggesting aberrant, prenylation-dependent vesicular traffic as a basis of glycosyltransferase increase and GSL remodeling.	pehpc	142-147	cathepsin A	Homo sapiens	0-3
26771826-9	2016	Inhibition of GSL synthesis with the glucosylceramide synthase (GCS) inhibitor N-butyl-1-deoxynojirimycin prevented U18666A-induced Gpnmb induction and secretion.	miglustat	79-105	cathepsin A	Homo sapiens	14-17
26771826-9	2016	Inhibition of GSL synthesis with the glucosylceramide synthase (GCS) inhibitor N-butyl-1-deoxynojirimycin prevented U18666A-induced Gpnmb induction and secretion.	3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one	116-123	cathepsin A	Homo sapiens	14-17
26393781-5	2015	Here, we directly compare the GSL complements from CHO-K1, COS-7, HeLa, HEK-293, HEPG2, Jurkat, and SH-SY5Y cells using an HPLC-based method requiring modest amounts of material.	carbonyl sulfide	59-62	cathepsin A	Homo sapiens	30-33